PINNACLE FERTILITY JOINS NATIONAL INFERTILITY AWARENESS WEEK TO RAISE AWARENESS AND EMPOWER THE INFERTILITY COMMUNITY – PR Newswire

"Infertility impacts 1 in 8 couples in the US. The chances that you know someone experiencing challenges on their journey to parenthood are pretty high. Yet the stigmatism surrounding it is still pervasive. Many of our patients struggle with this grief and isolation while navigating a complex journey. By promoting awareness and support, we are helping our communities feel empowered during this monumental, yet sometimes difficult life experience," shares Andrew Mintz, CEO of Pinnacle Fertility.

Throughout NIAW, Pinnacle Fertility and its network of clinics will be taking part in NIAW activities to increase awareness of infertility, break down stigmas and improve support for the infertility community. Physicians from each fertility practice within the Pinnacle network including Advanced Fertility Care, California Fertility Partners, Dominion Fertility, Institute for Human Reproduction, ORM Fertility, Reproductive Gynecology & Infertility, and Santa Monica Fertility are speaking up to support those struggling by sharing what #InfertilityStrong means to them via personal videos. Pinnacle's network will also be engaging on social media lifting up voices from the family building community and sharing how #WeCanAll raise awareness and support the infertility community. Pinnacle Fertility clinic team members will wear orange on Wednesday, April 27th as part of NIAW's #WearOrange campaign to spark more conversations about the disease that impacts 6.7 million people in the US each year.

Infertility Facts

1 in 8 couples (or 12% of married women) has trouble getting pregnant or sustaining a pregnancy. (2006-2010 National Survey of Family Growth, CDC)

7.4 million women (or 11.9% of women) have received infertility services in their lifetime. (2006-2010 National Survey of Family Growth, CDC)

Approximately one-third of infertility is attributed to the female partner, one-third is attributed to the male partner, and one-third is caused by a combination of problems in both partners or is unexplained. (www.asrm.org)

A couple ages 29-33 with a normal functioning reproductive system has only a 20-25% chance of conceiving in any given month. (National Women's Health Resource Center)

After six months of trying, 60% of couples will conceive without medical assistance. (Infertility As A Covered Benefit, William M. Mercer, 1997)

About Pinnacle FertilityPinnacle Fertility is the nation's fastest-growing physician-centric fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood.

For more information about Pinnacle Fertility, visitpinnaclefertility.com

Contact: Walt Conrad [emailprotected]

SOURCE Pinnacle Fertility

See more here:
PINNACLE FERTILITY JOINS NATIONAL INFERTILITY AWARENESS WEEK TO RAISE AWARENESS AND EMPOWER THE INFERTILITY COMMUNITY - PR Newswire

Nature Timespiral: The Evolution of Earth from the Big Bang – Visual Capitalist

Nature Timespiral: The Evolution of Earth from the Big Bang

Since the dawn of humanity, we have looked questioningly to the heavens with great interest and awe. Weve called on the stars to guide us, and have made some of humanitys most interesting discoveries based on those observations. This also led us to question our existence and how we came to be in this moment in time.

That journey began some 14 billion years ago, when the Big Bang led to the universe emerging from a hot, dense sea of matter and energy. As the cosmos expanded and cooled, they spawned galaxies, stars, planets, and eventually, life.

In the above visualization, Pablo Carlos Buddassi illustrates this journey of epic proportions in the intricately designed Nature Timespiral, depicting the various eras that the Earth has gone through since the inception of the universe itself.

Not much is known about what came before the Big Bang, but we do know that it launched a sequence of events that gave rise to the universal laws of physics and the chemical elements that make up matter. How the Earth came about, and life subsequently followed, is a wondrous story of time and change.

Lets look at what transpired after the Big Bang to trace our journey through the cosmos.

The Big Bang formed the entire universe that we know, including the elements, forces, stars, and planets. Hydrogen and massive dissipation of heat dominated the initial stages of the universe.

During a time span known as the Hadean eon, our Solar System formed within a large cloud of gas and dust. The Suns gravitational pull brought together spatial particles to create the Earth and other planets, but they would take a long time to reach their modern forms.

After its initial formation, the surface of the Earth was extremely hot and entirely liquid. This subsequent eon saw the planet cool down massively, solidifying some of the liquid surface and giving rise to oceans and continents, as well as the first recorded history of rocks.

Early in this time frame, known as the Archean eon, life appeared on Earth. The oldest discovered fossils, consisting of tiny, preserved microorganisms, date to this eon roughly 3.5 billion years ago.

The first era of the Proterozoic Eon, the Paleoproterozoic, was the longest in Earths geological history. Tectonic plates arose and landmasses shifted across the globeit was the beginning of the formation of the Earth we know today.

Cyanobacteria, the first organisms using photosynthesis, also appeared during this period. Their photosynthetic activity brought about a rapid upsurge in atmospheric oxygen, resulting in the Great Oxidation Event. This killed off many primordial anaerobic bacterial groups but paved the way for multicellular life to grow and flourish.

The Mesoproterozoic occurred during what is known as the boring billion stage of Earths history. That is due to a lack of widespread geochemical activity and the relative stability of the ocean carbon reservoirs.

But this era did see the break-up of the supercontinents and the formation of new continents. This period also saw the first noted case of sexual reproduction among organisms and the probable appearance of multicellular organisms and green plants.

In some respects, the Neoproterozoic era is one of the most profound time periods in Earths history. It bookends two major moments in the planets evolutionary timeline, with predominantly microbial life on one side, and the introduction of diverse, multicellular organisms on the other.

At the same time, Earth also experienced severe glaciations known as the Cryogenian Period and its first ice age, also known as Snowball Earth.

The era saw the formation of the ozone layer and the earliest evidence of multicellular life, including the emergence of the first hard-shelled animals, such as trilobites and archaeocyathids.

The Paleozoic is best known for ushering in an explosion of life on Earth, with two of the most critical events in the history of animal life. At its beginning, multicellular animals underwent a dramatic Cambrian explosion in aquatic diversity, and almost all living animals appeared within a few millions of years.

At the other end of the Paleozoic, the largest mass extinction in history resulted in 96% of marine life and 70% of terrestrial life dying out. Halfway between these events, animals, fungi, and plants colonized the land, and the insects took to the air.

The Mesozoic was the Age of Reptiles. Dinosaurs, crocodiles, and pterosaurs ruled the land and air. This era can be subdivided into three periods of time:

The rise of the dinosaurs began at the end of the Triassic Period. A fossil of one of the earliest-known dinosaurs, a two-legged omnivore roughly three feet long-named Eoraptor, is dated all the way back to this time.

Scientists believe the Eoraptor (and a few other early dinosaurs still being discovered today) evolved into the many species of well-known dinosaurs that would dominate the planet during the Jurassic period. They would continue to flourish well into the Cretaceous period, when it is widely accepted that the Chicxulub impactor, the plummeting asteroid that crashed into Earth off the coast of Mexico, brought about the end of the Age of Reptiles.

After the end of the Age of Dinosaurs, this era saw massive adaptations by natural flora and fauna to survive. The plants and animals that formed during this era look most like those on Earth today.

The earliest forms of modern mammals, amphibians, birds, and reptiles can be traced back to the Cenozoic. Human history is entirely contained within this period, as apes developed through evolutionary pressure and gave rise to the present-day human being or Homo sapiens.

Compared to the evolutionary timeline of the world, human history has risen quite rapidly and dramatically. Going from our first stone tools and the Age of the Kings to concrete jungles with modern technology may seem like a long journey, but compared to everything that came before it, is but a brief blink of an eye.

*Editors note: An earlier version of this article contained errors in the header graphic and an incorrect citation, and has since been updated.

This article was published as a part of Visual Capitalist's Creator Program, which features data-driven visuals from some of our favorite Creators around the world.

See the article here:
Nature Timespiral: The Evolution of Earth from the Big Bang - Visual Capitalist

Lidl Ireland to offer paid fertility leave to its staff – The Irish Times

Lidl Ireland has become the latest large employer to offer paid fertility leave to its staff.*

All employees who are undergoing IVF fertility treatments are being offered two days at full pay per cycle, regardless of length of service. There is no limit to the number of cycles for which employees can avail of the policy.

Although IVF is available only privately in Ireland, employers such as Vodafone and Pinterest have introduced fertility leave for staff in moves to a more family-friendly workplace. Some employers have also introduced extended leave for pregnancy loss and surrogacy.

The Government has plans to fund the provision of IVF for parents experiencing fertility problems but this is unlikely to happen until next year, as legislation regulating fertility clinics and domestic surrogacy must first pass through the Oireachtas.

Lisa Bohan, a sales operations manager with Lidl in the northwest, welcomed her employers new policy, even though it has come too late for her to avail of it.

Ms Bohan and her wife Catherine have a three-year-old son, Luca, and are expecting a girl in September. Both children were conceived using IVF.

It has been a long journey for us, emotionally and financially. IVF can be stressful, and some of this stress can be work-related, she said. When an employer is willing to accommodate your appointments and provide leave, that helps take away the stress and any associated stigma.

Ms Bohan says she tried to timetable fertility appointments early in the morning, before her working day, but this wasnt easy as she had to travel to Dublin for them.

Despite the lack of regulation, an estimated 10,000 IVF cycles and other advanced assisted human reproduction treatments are undertaken in Ireland every year. Many other women travel abroad for fertility treatment.

Each IVF cycle costed 7,000-8,500, when add-ons that can improve the success rate are included, Ms Bohan pointed out.

The experience of IVF can be distressing, both emotionally and physically, and is not a topic commonly discussed. I was fortunate to have a very supportive line manager and I am grateful that my openness has helped shape this policy for colleagues who may be undergoing this process in the future.

*This article was amended on April 25th, 2022

View post:
Lidl Ireland to offer paid fertility leave to its staff - The Irish Times

The Right to a Dead Baby? Abortion, Ableism, and the Question of Autonomy – Public Discourse

To what, precisely, is abortion a right?

Considering the disproportionate time it has spent as a central issue in American public discourse over the last half-century, the amount of confusion surrounding this topicfrom bioethics journals to dinner tablesis extraordinary. Indeed, the confusion is so severe that, much of the time, those who imagine they are discussing the same topic in fact have in mind very different kinds of acts.

Some of that confusion comes from intentional obfuscationwhen pro-life activists intentionally downplay the health risks of pregnancy, for example, or when pro-choice activists intentionally mischaracterize the development of the prenatal heart. But thats not what I have in mind here. No, the confusion that Im addressing in this article is a genuine one, coming out of two sincerely heldbut very differentunderstandings of the right to abortion. One imagines it as the right to bodily autonomy while another understands it is the right to reproductive autonomy.

My thesis in this article is that how we treat imperiled newbornsnot only after a failed abortion attempt, but also in a more traditional NICU (neonatal intensive care unit) settingis essential for fully grasping (and critiquing) the currently dominant understanding of the right to abortion. Furthermore, especially when we examine the central role ableism plays across both sets of issues, thinking about them together provides an anti-ableist critique that has important implications for both OB-GYNs and neonatologistsfor both prenatal and neonatal justice.

Two Rival Understandings

Judith Jarvis Thomsons abortion essay using the famous violinist analogy has become so ubiquitous that it is now a bit of a clich to call it the most famous article on abortion ever written. The argument is very familiar, but here it is in brief. Imagine that a famous violinist is attached to your body, dependent on you to continue living. Because abortion is analogous to removing the famous violinist from ones body, and the right to bodily autonomy means it is obvious that one need not stay attached to the famous violinist, the right to bodily autonomy means it is also obvious that one need not stay attached to the prenatal childwhich Thomson grants (at least for the sake of argument) is a human being.

Here we have the classic case for bodily autonomy and privacy, the framework that dominated the 1973 Supreme Court decision Roe v. Wade, and is still quite present in major parts of the abortion discourse in the United States. Slogans like Her Body, Her Choice! are still common rallying cries among activists. At the time these arguments were being developed, appeals to reproductive autonomy were not as common. Thomson, for instance, doesnt even attempt to make an argument (her awkward appeal to people seeds notwithstanding) that actually reflects how human reproduction works. Thats because reproductive autonomy is not Thomsons concern. Nor was it a concern of Justice Blackmun (much to the chagrin of Ruth Bader Ginsburg), or most of the dominant abortion-rights activists and thinkers during the 1970s and 1980s.

This would change, however. As more feminist-centered approaches came into prominence over the next decade or two, appeals to reproductive autonomy gained steam. They really hit their stride after the 1992 Supreme Court decision Planned Parenthood v. Casey, which explicitly argued:

For two decades of economic and social developments, people have organized intimate relationships and made choices that define their views of themselves and their places in society, in reliance on the availability of abortion in the event that contraception should fail. The ability of women to participate equally in the economic and social life of the nation has been facilitated by their ability to control their reproductive lives.

Here, the right to abortion is understood as part of what is necessary to control reproduction, which is seen as necessary for the economic and social equality of women. Clearly, by 1992, the reproductive autonomy argument had arrived in earnest. And yet there was still a hangover from the argument in Roe and other arguments coming from bodily-autonomy-centered feminists.

For instance, Casey and many other pro-abortion arguments still kept fetal viability in front of mind when it came to thinking about thresholds for limiting abortion rights. Such a threshold is relevant if one is thinking about bodily autonomy: Viable fetuses no longer need the womans body in a way that is analogous to the way the famous violinist needs anothers body. But if a womans right to abortion is based on her right to reproductive autonomy, then it isnt at all clear why fetal viability should be a bright red line for abortion rights. Indeed, it isnt clear why birth should be a bright red line either.

Pushing Reproductive Autonomy to Its Limits

The now two-decades-old debate over bans of so-called partial-birth abortiona procedure in which the baby is partially delivered and has the contents of her skull evacuatedwas a classic example of pushing on the bright line of birth. A floor debate between Senator Rick Santorum (R-PA) and Senator Barbara Boxer (D-CA) was revealing in this regard. Senator Santorum pushed Senator Boxer several times to give a precise account of when a baby was born and had full rights under the Constitution. He asked her directly: if the babys toe was still inside her mothers body, would that still be enough to put the childs life at risk?

Significantly, Boxer refused to give a clear answer to this question and other similar questions. And she did so despite the fact that naming the bright line precisely was at the center of the debate. After all, a baby killed via partial-birth abortion only has part of her head still inside her mother. Someone who thinks that is a relevant difference should give an account of what that is. Though the culture at large wasnt quite ready to go full reproductive autonomy at this point (including after birth) Senator Boxer alluded to this view when she gave the following response:

SANTORUM: But I would like to ask you this questionyou agree, once the child is born, separated from the mother, that that child is protected by the Constitution and cannot be killed? Do you agree with that?

BOXER: I would make this statement, that this Constitution as it currently issome want to amend it to say life begins at conception. I think when you bring your baby home [emphasis mine], when your baby is bornand there is no such thing as partial-birththe baby belongs to your family and has the rights.

This wasnt a slip of the tongue or the use of one or two words that were poorly chosen. Somewhere in Senator Boxers mind there was a distinction between birth understood as (1) mere separation from the body of the mother and (2) consent to take care of the child and take her into ones home.

A skeptic might wonder if this is just one view of one U.S. senator twenty years ago and therefore has only questionable relevance for my thesis in this article. But unfortunately, this kind of mindset about reproductive autonomy has done nothing but gain traction, at least in the developed West. This is especially true when we consider reproductive autonomy related to a babys disability.

We will see below that this issue is relevant to how we think about treating imperiled newborns in the NICU. Before we go there, consider this recent case from New Zealand: a mother was told by her physician that her baby likely had spina bifida and that she and her colleagues agreed the child would have no quality of life. Their recommendation was that the mother should have an abortion. Unfortunately, especially for those who wish to resist ableist judgements, this is all too common. But what happened next was quite revealing about the version of reproductive autonomy in play: when the mother revealed that she had no intention of having an abortion, her physician said that they could aim at the death of the child after birth. Here is how the mother narrated it:

When I let her know I had other plans, [the doctor] suggested that since I didnt want to terminate, I could wait until my son was born. If his disability was too severe she said I could choose to withhold treatment and let him die naturally then.

This obviously has nothing to do with a right to bodily autonomy, but rather with a right not to have a baby with a disability that is too severeeven after birth. In this case, the aim of the act in both the abortion and the refusal to treat was the same: aiming at the death of a child because of her disability. To follow the logic consistently here, in this context, the right to an abortion is the right to a dead baby. Again: this not a mere right to bodily autonomy, and there is no distinction made between the moral status of the prenatal human being and that of the neonatal human being.

The case of spina bifida is especially instructive, because it demonstrates how what happens after birth can be connected, morally speaking, to what is going on before birth. In the Netherlands, for instance, a neonatal euthanasia program called the Groningen Protocol at first had a considerable number of killings aimed at medically stable newborns with spina bifida. But as time wore on, the founder of the protocol, Eduard Verhagen, proudly reported that there was no slippery slope toward newborn killing, as some had suggested and feared. Instead, more and more physicians and families were turning to killing children with spina bifida before birth. Again, the aim of the act in both cases is the samethe death of a child because of her unacceptable disability.

Born Alive after a Failed Abortion

The connection between treatment of newborns and abortion was also on display when New York passed its Reproductive Health Act in January of 2019. Before the law was passed, this is what New York Public Health Law Section 4164 stipulated:

When an abortion is to be performed after the twentieth week of pregnancy, a physician other than the physician performing the abortion shall be in attendance to take control of and to provide immediate medical care for any live birth that is the result of the abortion. The commissioner of health is authorized to promulgate rules and regulations to insure the health and safety of the mother and the viable child, in such instances. Such child shall be accorded immediate legal protection under the laws of the state of New York, including but not limited to applicable provisions of the social services law, article five of the civil rights law and the penal law. The medical records of all life-sustaining efforts put forth for such a live aborted birth, their failure or success, shall be kept by attending physician.

Significantly, the Reproductive Health Act repealed this New York public health law and removed this layer of protection for babies born alive after a failed abortion. By insisting that a physician be present who didnt have the same aim as the physician doing the abortion, Section 4146 made a clear distinction between abortion as a right to bodily autonomy and abortion as the right to reproductive autonomy. The Reproductive Health Actbuoyed by an increasing sense that abortion is about reproductive autonomywas at pains to make sure the second physician was not present.

Significantly, recent debates over federal legislation similar to Section 4146 have been met with resistance by activists and legislators supportive of abortion rights. They argue that the law already protects these newborns and thus they do not need an extra layer of protection. One might find this a surprising reactionespecially coming from progressive activists who, in other cases, are deeply skeptical of the cultures ability to protect disabled children and are normally very interested in increasing governments role in protecting them. But it becomes easier to understand if one thinks about the right to abortion as a right to reproductive autonomywhich, in practice, is often the right to make sure a disabled baby does not survive.

How often does a baby survive an abortion attempt? There is disagreement about the actual numbers involved, but they dont seem to be trivial. The journalContraceptionestimates that up to 50 percent of labor induction abortions without digoxin can result in babies born alive. Despite what one might imagine are problems with gathering good data (obviously there are disincentives to reporting such cases), there are a few government entities that try to do so. Queensland, Australia, for instance, reports that about thirty babies survive abortion attempts each year. A few U.S. states keep track of the number of babies born alive after a botched abortion as well. The state of Minnesota, for example, reported three instances in 2018. If this is typical, then there are somewhere in the neighborhood of 150 cases each year in the United States.

Furthermore, a number of abortions sought at the postviability stage are directly related to a concern about the childs disability. My wife and I had our charmingly named genetic consult at twenty weeks gestation for little Thaddeus, and this was the standard for our hospital. For parents who choose to have an abortion just a couple weeks after such a meeting (sometimes after badgering from various members of their medical team), there is a good chance their child would be viable after a botched abortion.

Treatment Decisions for Disabled Newborns in a Non-Abortion Context

What do we do when a mother (or other parent or family) asks that a child not be resuscitated, treated, or cared for in a non-abortion context? The answer to this question also reveals much about how we think about the central issue of this article. Thankfully, because they are disassociated from toxic political and policy questions surrounding abortion, the available data on this question are much clearer.

First, it is worth pausing for a moment to briefly situate the medical profession in relation to disability. The British neonatologist and researcher John Wyatt found that physicians consistently rate the quality of life of their disabled patients worse than the patients themselves do. Something similar has been found withrespect to disabled or sick adolescents and their families. Disability bias present in CPR providers leads some to consider their patients as socially dead and therefore unworthy of being saved. Neonatologists often think that babies born with severe disabilities have fates worse than death. And when confronted with the fact that patients generally prefer length of life to quality of life, physicians might feel surprised and admit we think we know what is best for a patient, but this is often wrong.

We must keep this ableist mindset squarely in mind when we think about how treatment and care decisions are made for disabled newborns. This is especially true when physicians are asked to make judgments about what would constitute profound disability or unacceptably severe morbidity. Such categories are wide open to subjective interpretation based on differing foundational values and philosophical and theological visions of the good.

John Lantos, an eminent bioethicist and neonatologist at the University of MissouriKansas City School of Medicine, points out that disagreements between parents and neonatologists about treatment decisions are not uncommon and usually come down to questions about the value of life with severe physical or cognitive impairments. Furthermore, though neonatologists say they want shared decision-making with parents, Lantos notes that in fact they do not practice it, and few allow the parents preferences to prevail when there is a conflict. Furthermore, even when shared decision-making is practiced, the power and knowledge imbalance very often means that the facts are framed (via choice architecture) by the physicians background values, biasing the discussion toward her point of view.

Despite the ableist biases still in play, Lantos notes that changes in societal attitudes toward people with disabilities have contributed to some changes in clinical practice. Indeed, he notes that back in the 1970s surgery for correctable anatomical malformations in babies with trisomy 21 [Down syndrome] used to be within the zone of parental discretion and only a small minority of doctors would have sought protective custody to operate on a baby with Downs syndrome. Similarly, treatment of babies with Trisomy 18 used to be considered futile, but now has moved to the zone of parental discretion.

Lantos also notes that parents are more accepting of disabilities than are physicians, which offers hope that the medical community will continue to grow out of its ableism. Especially important for this process is the challenge physicians and ethicists like Cummings, Mercurio, and Paris offer to physicians in this context: Engage in consistent and extended communication over time, foreground all values in play and talk openly about ones biases, and commit to building trust. This culture of encounter, if pursued authentically, could push physicians still further along the path of justice for persons with disabilities.

Unfortunately, even these kinds of laudable frameworks for navigating conflicts in decision-making between parents and physicians will leave huge problems with ableism unresolved. Lantos points out that with increased prenatal detection of disability, many parents who dont want such a child will have an abortion. As a result, when such children do make it to birth, a higher proportion of their parents will ask for treatment, which neonatologists may not want to give. (Id also add that it may result in more disabled children born alive after a botched abortion.) But what happens when parents have an ableist bias about the childs quality of life? As Lantos points out, a commitment to shared decision-making does not mean that any decision is ethically defensible. At times, a treatment decision will need to be imposed on parents who are aiming at the death of their disabled children.

Cummings, Mercurio, and Paris helpfully cite the American Academy of Pediatrics guidelines for Nonintervention or Withdrawal of Intensive Care for High Risk Newborns this way:

As noted above, concepts like unacceptably severe morbidity are subjective, but with a justice-centered, anti-ableist lens they can be more helpful. With such a lens, almost no cases would be thrust into the first category and many more cases would be put into the second. Instead of capitulating to the ableist view that fellow human beings with Down syndrome, spina bifida, Trisomy 18, etc. have unacceptably severe morbidities, we would welcome them as full and equal members of the human family. It is already the case, as Mercurio and Cummings point out, that in certain circumstances treatment of newborns is considered obligatory and will be provided even when ableist parents insist that the baby be left to die. As part of our cultures growing resistance to ableism, however, medical teams must be significantly more aggressive in imposing such treatment on parents who want to aim at the death of their child because of her disability.

Consequences for Ableist Judgments That Aim at Death?

But suppose a physician does not follow this path? What if, instead, she either cooperates with the parents or imposes on the parents (directly or indirectly, via choice architecture based on her particular background beliefs) a treatment decision that aims at the death of a child because of her disability? What should the consequences be for such an act?

Before discussing this, let us be clear about the moral analysis. Not all refusal to aid a newborn child is aiming at death. Some might be attempts to do something else (like removing overly burdensome treatment), with death as a foreseen and unintended consequence. For instance, one might forgo painful chemotherapy or chest compressionsand be absolutely delighted that the child, against all odds, survives. That delight is a clear indicator that one was not aiming at death.

Some forgoing or cessation of treatment, however, is in fact aiming at death. If one comes to the conclusion that it is better that a child die because of her disability, and one removes a ventilator with that aim in mind, and the child, against all odds, starts breathing on her own and survives, then one is surely not delighted, for the goal was to end up with a dead child. This, in fact, was precisely the kind of situation presented by the famous Baby Doe case in which the parents, on advice from their physicians, refused to have a common and safe surgery to repair esophageal atresia because their child had Down syndrome.

The fact that everyone knew that this was aiming at the death of a child because of her disability sent shockwaves throughout the United States in the early 1980s. Pro-lifers and disability rights activists teamed up with the Reagan administration to enact HHS regulations and pass federal laws to protect disabled children like Baby Doe. Under the Child Abuse Amendments of 1984, cases of refusal of treatment of a newborn go to a review board and possibly to state protective services. If a medical team today worked with parents to aim at the death of an infant with Down syndrome in this way, they could be held accountable under child abuse and negligence statues.

Id add that in our current moment, which gives particular legal attention to disabled populations as a protected class, there could be more legal liability for medical teams who engage in grossly ableist and abusive behavior toward children with Down syndrome. Under federal law, which as of 2009 includes the disabled as a protected class, someone who engaged in child abuse because of a childs disability could be charged with a federal (and state) hate crime as well. And of course it wouldnt just be children with Down syndrome that are legally protected from this kind of child abuse: aiming at the death of children with disabilities related to spina bifida, Trisomy 18, and many other conditions would also be prohibited.

Saving vs. Creating and Reconnecting to Abortion

Why hasnt this kind of moral and legal analysis caught on in neonatal bioethics and clinical ethics circles? Janvier and Mercurio offer us a fascinating insight that may help explain what is going on here. They present two casesone about a preterm (born at twenty-four weeks gestation) newborn named Catherine and one about a previously healthy two-month-old baby named Sam. Both meet with severe health problems, and both have about the same potential for long-term disabilitythough Sam actually has a lower chance of survival. Their research found that in many hospitals in the U.S., Canada, and elsewhere, intensive care treatment would be initiated routinely for Sam, but considered optional for Catherine. This despite not only Catherines better chance of survival, but the fact that most ethical guidelines (from the American Academy of Pediatrics to the Nuffield Council on Bioethics) insist that the ethical principles for treating newborn children are no different from those for treating older children and adults.

The reason for this, Janvier and Mercurio suggest, is because preterm babies lack the interpersonal attachment that older babies and children have, and health care providers may not consider them to have the same personhood as older infants who went home. Because of this distinction, the authors suggest that providers may think of themselves as saving Sam, who now has a disability, while they are creating a person with a disability if they successfully treat Catherine. If true, this insight would certainly help explain why a clinical and bioethical culture would react with horror to what happened to Baby Doeand to withdrawing or withholding vital treatment of older disabled children because of their disabilitybut have a different view of the very same judgments and actions happening in the neonatal intensive care unit.

This distinction between saving and creating is obviously deeply problematic. Newborn children are fellow human beings and must have full legal protections and supports enjoyed by older children. But Janvier and Mercurios insight helps us make the connection back to abortion. Philosophers like Peter Singer, Michael Tooley, and others are correct in noting that, if we do not consider the human fetus a person, then we cannot see the newborn infant as a person either. Both are fellow members of the species Homo sapiens, but if we are to avoid speciesism we must insist not on common humanity but rather on morally relevant traits like rationality, self-awareness, and interpersonal relationships. The case of Catherine above is particularly instructive for their position: born at twenty-four weeks gestation, she is actually less developed than many prenatal human beings when it comes to morally relevant traits like these.

But if we reject the position offered by Singer, Tooley, and those making the saving vs. creating distinctionif we insist that neonatal human beings deserve legal protection from having their deaths aimed at because of their disabilitythen we must also insist that prenatal human beings deserve legal protection from having their deaths aimed at because of their disability. And this means rejecting the idea that the right to abortion is the right to reproductive autonomy. The right to abortion as it existed under Roe was the right to bodily autonomynot the right to a dead baby. It is of course deeply wrong to refuse to aid a disabled child after a botched abortion because one doesnt want the disabled child to survive, but it was just as wrong to aim at the death of the prenatal child in the first place.

One might object with an appeal to moral status here, arguing that there is a morally relevant difference between a prenatal child and neonatal child. But the fact that we are making special space for nontreatment of neonates after botched abortions (recall the discussion of New Yorks Reproductive Health Act above and the repeal of the two-physician requirement)and for nontreatment of neonates that we dont allow for older childrenmeans that we dont think of the neonate as having a special status that would overrule reproductive autonomy. The corrective here is to treat all fellow members of the human family (prenatal, neonatal, and older) with radical moral and legal equality.

Disability and Prenatal Justice

The state of Ohio recently passed a law protecting prenatal human beings with Down syndrome from being killed via abortion because of their disability. The law was upheld in April of 2021 by the Sixth Circuit Court of Appeals as not creating a substantial obstacle to a womans ability to choose or obtain an abortion. Judge Alice Batchelder wrote the lead opinion, which argued that the State of Ohio has a legitimate interest in protecting the Down syndrome community, keeping doctors from becoming witting participants in Down-syndrome-selective abortions, and ensuring that women are not coerced by the medical teams.

Women and families face incredibly pervasiveand coercivepressure to have an abortion when their prenatal child is thought to have Down syndrome. One research project focused on the lasting, traumatic flashbulb memories that women report as a result of negative experiences with medical staff, including a lack of compassion, pressure to terminate their pregnancy, and pessimistic expectations about outcomes for their child and family.

For a specific example, consider the case of Lorraine, who was pregnant at the age of forty-five with a boy she had already named Jaxson. As reported by the BBC, Lorraine agreed to have an extra screening and blood test, not because she and her husband would have an abortion, but because her midwife said they would get longer to see Jaxson on the ultrasound screen. The sonographer told the parents that the baby showed signs of having Down syndrome and suggested that they get more testing via amniocentesis, a test that slightly increases the chance of miscarriage. Partly because Lorraine had lost a baby the previous year, but also because she would never have the abortion, she refused the extra test. The sonographer became very aggressive and said women like you make me sick. Why bother having a screening at all if youre not going to do anything about it?

The same BBC story told the story of Emma, who was offered 15 terminations, even though we made it really clear that it wasnt an option for us. . . . [T]hey really seemed to push and really seemed to want us to terminate. Her medical team made a point of saying she could have the abortion very, very late in her pregnancy. I was told that until my baby had started traveling down the birth canal, I could still terminate, Emma said.

Significantly, the UK doesnt allow normal prenatal children to be killed that late in pregnancy. This fact led a twenty-six-year-old British woman with Down syndrome named Heidi Crowter to sue the UKs Department of Health and Social Care, arguing that a provision that makes it legal to kill people like her up until birth is an obvious example of wrongful discrimination on the basis of disability. Though a UK court justruled against her, it should be clear from the above arguments that her position was the correct one.

Happily, Ohio currently does a much better job of defending prenatal justice for disabled children. Their law says:

No person shall purposely perform or induce or attempt to perform or induce an abortion on a pregnant woman if the person has knowledge that the pregnant woman is seeking the abortion, in whole or in part, because of any of the following:

(1) A test result indicating Down syndrome in an unborn child;

(2) A prenatal diagnosis of Down syndrome in an unborn child;

(3) Any other reason to believe that an unborn child has Down syndrome.

Furthermore, anyone found to violate this law in Ohio is guilty of a felony of the fourth degreewhich means that the state medical board shall revoke a physicians license to practice medicine in this state and he or she will be liable in a civil action for compensatory and exemplary damages and reasonable attorneys fees. Good on Ohio for defending the rights of the disabled.

There is a whole separate debate to be had about the right to abortion understood as the right to bodily autonomy. (At the heart of that debate, incidentally, is the invocation of viabilityan ever-shifting concept that, as Lantos points out, has increased dramatically for babies at twenty-two and twenty-three weeks gestationand will shift even more dramatically with the development of artificial wombs.) But what I have shown in this article is that the deeply ableist problems with (non)treatment of newborn infants are logically, morally, and sometimes clinically connected to deeply ableist problems with abortion being understood as reproductive autonomy.

Matters of Public Policy: the Maryland and California Bills

Im quite sensitive to the critique that professorsand especially bioethicistscan often take dramatic speculation into the realm of the utterly implausible. Especially because of the great evil being discussed in this article, one might think that Ive cherry-picked a few stories or authors to make my argument. But supporters of two billsone in Maryland and one in Californiaare moving explicitly to defend aiming at the death of newborns by omission, in precisely the ways Ive described.

The Maryland bill, for instance, would eviscerate any penalty for aiming at the death of a newborn child by omission for up to twenty-eight days after birth:

This section may not be construed to authorizeany form of investigation or penaltyfor a person: (1) Terminating or attempting to terminate the persons own pregnancy; or (2) Experiencing a miscarriage, perinatal deathrelated to a failure to act, or stillbirth [emphasis mine].

Interestingly, the language in the California bill uses many of the concepts I have invoked in this article, though it oddly connects the right to refuse to treat a newborn human being to the right to privacy:

The Legislature finds and declares that every individual possesses afundamental right of privacy with respect to personal reproductive decisions, which entails the right to make and effectuate decisionsabout all matters relating to pregnancy, including prenatal care, childbirth, postpartum care, contraception, sterilization, abortion care, miscarriage management, and infertility care.

Because of this finding, the bill would mandate that there could be no civil or criminal charges filed for actions or omissions that result in miscarriage, stillbirth, abortion, or perinatal death.

These proposed laws notwithstanding, there is no right (of privacy or otherwise) to a dead baby. Indeed, the idea is especially heinous if, as is too often the case, one seeks her death because one finds her disability unacceptable. This not only means resisting the kinds of laws being proposed in Maryland and California; it means refusing to distinguish between the equal justice under law owed to both neonatal and prenatal human beings.

Follow this link:
The Right to a Dead Baby? Abortion, Ableism, and the Question of Autonomy - Public Discourse

Is it ethical to have kids in the climate crisis? – Maclean’s

The planet is, quite literally, on fire: a third of humanity is now exposed to deadly heat stress. Nearly a million species are facing extinction, and a global pandemic still lingers. Extreme weather is increasing in frequency and intensity, and the future is looking even more dire: UN Secretary-General Antnio Guterres calls the latest Intergovernmental Panel on Climate Change report a damning indictment of failed climate leadership.

Small wonder, then, that eco-anxiety is on the rise, particularly among those young enough to know that theyand their childrenare heirs to a damaged and diminished world. Last year, Caroline Hickman, a specialist in the burgeoning field of climate psychology at the University of Bath in the U.K., reported on a study she co-authored that surveyed 10,000 youths aged 16 to 25 across 10 countries. Half reported feelings of anger, helplessness and shameemotions exacerbated by the belief that their governments were lying to them about delivering on green and humane policies. Some are outright refusing to plan for a future preordained to be nasty, brutish and short. As for their so-called eco-reproductive concerns, the results were jarring: 40 per cent of respondents expressed a reluctance to have children.

At 35, Britt Wray, author of the new book Generation Dread: Finding Purpose in an Age of Climate Crisis, falls outside of Hickmans respondent pool, but she, too, has heard the warnings and witnessed inaction her whole life. Wrays book is an extraordinary exploration of the emotional and psychological toll environmental chaos is already exacting. Its also a road map out from under that burden, made all the more compelling by the way it tracks her own journey. Born and raised in Toronto, Wray earned a Ph.D. in science communication at the University of Copenhagen. She is now a cross-appointed postdoctoral fellow at the London School of Hygiene & Tropical Medicine and Stanford University in California, studying the implications of the climate crisis on mental health. She knows the existential angstand its corrosive effectsintimately.

These fears once buffeted Wray badly, leaving her feeling isolated, despairing and uncertain of the wisdom and morality of bringing children into the world. Now, shes realized that there is still an opportunity to mitigate the worst outcomes. Shes able to visualize a better future for herself and, above all, for her seven-month-old son, Atlasa child of our times in every conceivable way. Researching and writing this book brought me to a position where I could have him, says Wray. There is a direct line from the radical hope my findings gave me to Atlas. If I were left up to my own ruminations, I dont know if I wouldve been able to dig myself out of that hole and see having him.

***

Growing up, Wray was as attuned to climate crisis projections as any millennial, but far from obsessed. That changed rapidly after she enrolled at Queens University in Kingston, Ontario, in 2004, majoring in biology. The sixth mass extinction, the ongoing annihilation of habitats and wildlifewhose populations have dropped by more than two-thirds since 1970is inextricably linked to human resource extraction. It was a crisis impossible for a biology student to ignore. A lot of my courses were focused on conservation biology and ecology, she recalls. Through it all, I was constantly bearing witness to more data about population decline, species decline, anthropogenic effects on wildlandsthese were my first environmental stressors. Wray was soon fixated on climate change, immersing herself in the literature and becoming less interested in doing science than developing innovative ways of spreading news of its discoveries. I wanted to bring a creative storytelling angle to what I was learning, she says.

MORE:Emily St. John Mandel cant stop writing about pandemics

In 2015, during her doctoral studies in Copenhagen, she met her future husband, Sebastian Damm Wraynot through her climate activism but in an equally modern way: on Tinder. Denmark, of course, was particularly attuned to the failure of the 2009 Copenhagen climate summit to effect meaningful reductions in carbon emissions. As a result, Wray moved ever deeper into climate worry. She read one IPCC report after another: most were concerned with the planet reaching tipping points that would destroy food and water supplies. All of them insisted that humanity was running out of time to avoid the worst outcomes.

In 2017, when she and Sebastian first started talking about having a child, Wrays response was a visceral one. A deep sense of grief and despair came crashing over me when I considered what it would mean to deliver a child into this world, she writes in Generation Dread. Desperate to see what her peers felt, Wray started reaching out to experts and, via social media, to ordinary people, parents and non-parents alike. There, she found a well-establishedif largely undergroundriver of thought on human conception, one that was rapidly devolving under the pressure of eco-anxiety.

This kind of anti-natalist thinking isnt new: there is a long-running tradition of it, found as far back as Ancient Greek philosophy and early Christianity. It argues that life always ends badly and should be stopped from even beginning. (Babies, as the second-century Christian Encratites put it, were merely fresh fodder for death.) Since the 1990s, proponents of voluntary human extinction have proclaimed that the only way humanity can save life on this planet is by a slow-motion mass suicide, protecting the biosphere by ceasing to procreate. Academics have pointed to the effects environmental degradation is already having on involuntary human infertility: sperm counts in Western countries have dropped by half since 1973, which correlates with rising pollution and heat levels.

More pertinent to Wray were the women of childbearing age who delayed having children due to contemporary socioeconomic factors: the end of job security, high housing costs and lengthy educations. All of these markers of adulthood were being affected by climate change. Wray took note of how the label selfishonce levelled at adults who didnt have childrenwas beginning to apply to those who did. There was one main consideration upholding child hesitation among the climate-aware: the pressure every new child puts on the environment. In the emissions-pumping Americas, the answer is, a lotthe average American child adds more than 9,000 cubic metric tonnes of carbon to their parents carbon footprint, while a Bangladeshi child adds only 56 tonnes to theirs.

Wray, meanwhile, was considering a different question: what havoc would a deteriorating world wreak on the health, happiness and security of a child? During her research, she found many who shared that fear. She spoke with a young mother who had waking nightmares the whole time she was pregnant with her son. I had all these catastrophic images in my head, she said. Of me running with my child and having nowhere to sleep, or of us starving, or him experiencing his parents dying. Wray also spoke with teenagers who were angry that their parents had brought them into a world spiralling downward. What haunted me was the possibility that if we had a kid, theyd grow up and become aware of whats happening. That theyd turn to us one day, understanding that we knew all of this was coming, and yet still chose to put them here . . . says Wray, trailing off. Would the situation ever become so oppressive that they would really rather not have been born?

The contemporary, climate-driven movement broke into popular consciousness when BirthStrike was founded in Britain in 2018. Its founders were a group of millennials who, as much as they wanted children of their own, believed reproduction was both dangerous for children and immoral given our collective environmental situation. A year later, BirthStrike changed its name to Grieving Parenthood in the Climate Crisis, or GPCC, in order to distance itself from populationism, the belief that too many people were the root cause of climate deterioration. The GPCC wanted to be clear that its members child-bearing hesitation is linked not to the size of the worlds population, but to individual carbon footprints. In that way of thinking, they were not alone: a more amorphous school of thought known as GINK (Green Inclination, No Kids) is now flourishing. Even prominent politicians like Alexandria Ocasio-Cortez have gone on record asking, Is it okay still to have children?

Britt Wray.

Wray says she was particularly affected by perspectives of people from historically marginalized groupspopulations who are already on the front lines, whose lives and culture are intimately linked to land and water. Indigenous peoples around the world are disproportionately threatened by climate change. Yet Anishinaabe author Waubgeshig Rice, author of the climate-crisis thriller Moon of the Crusted Snow, told Wray he didnt know of anyone from his Wasauksing First Nation, 250 kilometres north of Toronto, whod decided against having kids for environmental reasons. In his community, Rice explained, children are essential, both as a means and living symbol of cultural continuity. Its being able to say, We are still herethe future includes us. It was a message echoed by Black women Wray interviewed, including her friend, the anti-racism activist Rachel Ricketts. While expressing compassion for Wrays personal dilemma, Ricketts pointed out that anxiety was nothing new for her people. Welcome to having to worry about the livelihood of your children, she said. My mother had to do it, my mothers mother had to do it. My ancestors had their children stolen from them and sold.

RELATED:Meet the muses behind Robert Munschs most iconic stories

Hearing that message of certainty from communities whose children have been taken from themin living memory, no lessand who are still seeking their unmarked and lost graves, had a powerful effect on Wray. She realized how much of her fear arose from a place of privilege. Those who have had secure, comfortable lives, it forms their benchmark for existence. That can be very fundamentally shaken by climate awareness, Wray says. So, okay, middle-class white girl is afraid because the world doesnt feel safe anymore. It is good to realize that many peoplepeople who have not had the luxury of feeling secure, who know the world is full of tearsthey find ways of cultivating joy amidst the tragedy.

***

Wray still wasnt sure. At first, her conversations with other climate-aware peopleand the hope they providedbarely balanced out the emotional toll of her everyday communications work: It was eight-plus hours a day of paying attention to new reports on the climate crisis and to the lack of effective action. Her eco-anxiety remained high and, at times, crippling. She was beginning to realize she couldnt even talk about a shared future with Sebastian, the person she loved most, without applying what she calls a filter of apocalyptic possibility.

In one intense 24-hour period in Denmark, Wray engaged in an emotional late-night talk with friends about the magnitude of the climate crisis, burst into tears with another friend at breakfast the next morning, and dined with her father-in-law as he made polite but insistent inquiries about grandchildren. She followed that with even more tears on the train ride home. When Wray read Caroline Hickmans four-stage eco-anxiety conceptual frameworka list of increasingly intense symptoms that allows therapists to place patients along a spectrumshe easily saw herself in the Significant group, the last stage before Severe, and the first where people choose to forgo having children.

And yet Wrays longing for a child grew over the years, even as her existential dread remained immovable. Almost all the pressure she felt was on the pro-child side: her own desire; Sebastians desire; the expectations of both families; helplessly watching two clocks simultaneously tick toward midnight (the entire planetary ecosystem and her own fertility). She came to believe that a child represented skin in the game, providing an ever-urgent incentive to fight for a better world.

READ:Zarqa Nawaz had a hit show, then a decade-long dry spell. Shes ready for her second act.

In 2018, the Wrays moved to the U.S., first to New York and then later to California, when Sebastian, a diplomat, took a role as the chief strategic advisor to Denmarks tech ambassador to Silicon Valley. Wray took up the Stanford portion of her fellowship. The biggest shift, though, was in her consciousness, prompted by the research she gathered and internalized while writing Generation Dread between 2017 and 2020. Gone are the breakdown crying fits she once had. I found not only the coping tools, she says, but just as importantly, others who mirror my feelings and validate them, when once I thought I was really alone. Thats what makes you feel like youre crazy.

In the end, there was no eureka moment that pushed her toward motherhood. Wrays mindset changed as she researched, gleaning insights and advice from climate therapists, and full of admiration for the hard-won resilience of the historically marginalized. Eco-anxiety is more than understandable: it is justified, she writes. We ought to mourn the coming losses to the natural orderand to human civilization. At the same time, we should do what we can to save whats left: by 2020, she and Sebastian simply decided to have a child, and in January 2021, they laughed and cried over a positive pregnancy test.

If Generation Dread has one overriding theme, its that community saves, and that trust and mutual care are its foundations. I learned to get a grip on my own emotions and develop much more flexible thinking around my child-bearing dilemma, says Wray. The basic question changed from, Is it okay to have a child? to Whats required when one decides to have a child today? How do we parent in the climate crisis? Now that her book is done, there is time for Wray to probe that question in day-to-day life. Were sleep training, she says. Atlas is smiling and laughing and bringing a lot of joy. Good news for our turbulent world.

This article appears in print in the May 2022 issue of Macleans magazine with the headline, Earth mother. Subscribe to the monthly print magazine here.

Read this article:
Is it ethical to have kids in the climate crisis? - Maclean's

First Endangered Red Wolf Pups Born in the Wild Since 2018 – EARTH.ORG

Renewed hope for the critically endangered red wolf species as six new pups were born in North Carolinas Alligator River National Wildlife Refuge.

For the first time in four years, a litter of six red wolf pups has been born in the wild, the US Fish and Wildlife Services Red Wolf Recovery Program confirmed, sparking new hope for the future recovery of the critically endangered species.

This new litter is the first wild-born litter of red wolves since 2018. This red wolf pair was formed through the combination of several management actions and the two red wolves subsequently following their natural instincts in pairing, establishing their territory and mating, the Red Wolf Recovery Program shared on Facebook. Every generation yields a newborn hope for the red wolf a cause for joy and celebration!

The new arrivals (4 females, 2 males) were born to a pair of wild red wolves in Alligator River National Wildlife Refuge in eastern North Carolina amid renewed conservation efforts by the US federal agency since early this year.

Since 2015, The US Fish and Wildlife Service has largely abandoned its recovery efforts. But the agency announced in February that it will commit significant resources to revitalise its programme and ensure a full recovery for the species in the wild. One action they took was the release of seven captive-bred red wolves into the wild population, which is made up of a pack of two adults and three pups.

Once widely common in eastern and south central regions of the US, the red wolf is now one of the most endangered species in the US, with less than 20 individuals remaining in the wild across five sparsely populated counties in eastern North Carolina. Though the animal is protected under the Endangered Species Preservation Act in 1967, its population numbers have dropped significantly over the past few decades due to human activity such as hunting and habitat destruction.

In 2021 alone, seven red wolves were confirmed killed by vehicle strikes, gunshots and other unknown causes, with the former two remaining to be the biggest threats to the species.

The dwindling population has also not added any new pups in recent years either. The last birth of red wolf pups occurred in 2018, when four pups were born, highlighting the grim future for the survival of the species.

But under the new programme, the Service has renewed matchmaking efforts to boost reproductive processes and encourage adult wolves to pair, establish their territory, and mate.

Many environmentalists have praised the agencys efforts and hopes for continued success. Theres a clear cause-and-effect relationship between the Services recovery efforts and the survival and reproduction of red wolves in the wild, said Perrin de Jong, from the environmental non-profit Center for Biological Diversity. Its tremendously encouraging to see the agency trying to protect and recover wild red wolves again. My heart is filled with hope at the sight of a new generation of red wolves taking their rightful place on the landscape.

Featured images by: Red Wolf Recovery Program, US Fish and Wildlife Service

Here is the original post:
First Endangered Red Wolf Pups Born in the Wild Since 2018 - EARTH.ORG

The Curse of Knowledge and Whole Genome Sequencing – American Council on Science and Health

So Whats Wrong with Whole Genome Sequencing?

Whole genome sequencing is the process of determining the entirety, or nearly the entirety, of theDNAsequence of an organism'sgenome. It has been offered to determine an individuals risk of future disease based on a subjects DNA mismatch from normal. However, other than relatively rare monogenic diseases (caused by one gene), most illnesses and traits result from multiple gene interactions coupled with environmental and lifestyle.

Accuracy or Tea Leaf Reading?

Whole genome sequencing might prove useful to someone already sick to concoct an individualized precision-medicine cocktail. But for predicting future disease, based on the available data we now have, its validity is akin to reading tea leaves.

Even if the interplay of environmental, lifestyleand multiple genetic variables could be addressed, all this data can do is project a population -- not individual -- risk of disease. Thats the first problem with extrapolating the new knowledge, its not precise. But there is more.

The extent of ethnic influences on genetic expression is not yet known. Whole genome sequencing data has focused on white Europeans, constraining extrapolation to other ethnicities. Recently, 100,000 whole genome sequences, half from African-Americans, Hispanic, or Asian, have been sequenced, supposedly making the database more relevant to the non-white population. But much of the data is only available to researchers associated with certain American universities. Exactly how much of the 50% of the data collected belongs to which of the subgroups is not readily known, rendering reliance by non-whites risky.

The Death of Privacy

Some enthusiasts ignore the accuracy concerns and call for the creation of a national DNA database where we would assemble the whole genome package of all our citizens. the next step in Pandoras progress. The British have been planning (plotting?) this since 2013. This whole genome sequence data supposedly would be anonymized (but the anonymization would be reversible and simple to untangle). Its use is proposed to be available to private companies, including Google, without peoples knowledge and consent. Suffice it to say, the abuses, including privacy violations, are rather horrific to contemplate.

Genomed at Birth

Compiling whole-scale genomic information for a willing and consenting adult might fall under the realm of autonomy, although the cost for such testing would create its own disparities and social justice concerns. Engaging in the same practice for newborns, as proposed by the British Newborn Genomes Programing project, poses its own problems. While the information could disclose risks of hundreds of conditions, some are without cure or preventive measures. That knowledge might well be considered a burden not a blessing.

In the US, some 29 diseases are routinely screened for at birth. But these are diseases where early diagnosis and treatment are available, increasing the chances of healthy development and reducing death. Many such screens are mandatory, although some opt-outs do exist.

Using whole genome sequencing to achieve this end would disclose diseases, both with treatment or preventatives and those without. Of what use would the latter of knowledge be?

Consider the discussion of Huntingtons Chorea by my colleague, Dr. Dinerstein, disclosing that most adults wouldnt even avail themselves of knowing they would have a disease without cure or treatment or preventive measures even if it were available.

Can We Handle the Knowledge?

Another objection is, do we have the person-power to address findings that might be treatable? At recent conferences discussing the issue, objections were voiced by the healthcare industry, which anticipates an overflow of conditions without sufficient personnel to treat them, along with questions regarding the training of healthcare workers [and genetic counselors].

And What About the Rights of the Child?

Amongst issues that were not raised were the rights of the child. It is one thing to identify childhood diseases that a parent might be able to prevent. But the Whole Genome Project doesnt limit itself to illness by age knowledge of the panoply of diseases for which a baby is at risk in their future life would be available to the parent and, by extension, the siblings. Perhaps a child, on reaching adulthood, wouldnt want their parent to know they are at risk of depression, Alzheimers, or diabetes? Should that knowledge be made available?

Pre-Implantation Genetic Testing

Pre-implantation Genetic Testing (PGT) is now used to identify monogenetic diseases in newborns testing to determine illness caused by a single gene. It determines which embryos are suitable for implantation. In the UK, its use limited - legal to prevent serious illness.

Genomic Prediction is the creator of LifeView, an advanced genetic testing platform for embryos for IVF. We help couples have the healthiest child possible, protecting your baby from genetic risks that run in your family."

Recently, companies have expanded single-gene tests to encompass a broader range of genes - to assess not just a specific disease but the likelihood of a particular trait. Companies like Genomic Prediction advertise polygenic embryo screening, or PGT-P, to assess genetic data involving multiple genes (although not the whole genome) to predict the healthiest baby. [2] These PGT-P tests evaluate a series of genes arguably related to healthful traits but could be gerry-rigged to select for intelligence, aesthetics, or athleticism in the future.

Genomic Prediction and its competitors use algorithms in their analysis, relying in some cases on adult populations that may not even be relevant. Even if a PGT-P trait was relatively accurate in assessing relative (population) risk of disease, the value in predicting absolute risk (actual risk in individual) is very small. A 50% increased population risk translates into an absolute risk of that trait in an individual of 0.5% - a hundred-fold reduction.

At present there is no evidence that PGT-P can reliably predict the relative risk of an embryo developing a certain trait of disease.

Dr. Francesca Forzano, Consultant in clinical genetics Guy's & St Thomas' NHS Foundation Trust, London

The best the tests can currently do is approximate which embryo is the hardiest and has the least risk forfuture biologic disease at the time of selection. The effects of environmental stressors, including pregnancy, arent included in the analysis giving the would-be parents a false sense of security.

It's not surprising that the European Society of Human Genetics, the European Society of Human and Reproduction Embryology, and the American College of Medical Genetics have released statements advising against using polygenic risk scores for embryo selection. In the UK, its use is illegal.

Solomons Choice

Some bioethicists, like Hank Greeley, oppose the technique, leaving open the possibility of its future use, should they prove more accurate, claiming well-informed parents should be able to make their own decisions.

But the process also determines which embryos are rejected. Even if the testing proves more accurate, its use might be a societal tragedy. Selecting the ostensibly healthiest embryos means the less healthy ones are rejected. Superficially, this might seem beneficial, individually as well as societally. But this process also selects against geniuses such as Stephen Hawking, who suffered AMLS, or schizophrenic Nobel Prize winner John Nash.

Determining the healthiest or best baby to be born might evidence hubris rather than wisdom on the part of he or she doing the selecting.

Future Risk

The problems raised by PGT-P, which confines itself to groups of genes, are magnified by attempts to perform whole-genome sequencing at the embryo stage. These additional tests promise to identify the entire genomic structure of the would-be child before it is even born. Now, instead of selecting the healthiest baby, parents might specify one that is also beautiful and brawny weighting whichever traits they deem most important to them.

Relevant molecular and statistical techniques published last month in Nature Medicine touted a high degree of validity for this technique in predicting genetic risks for adult-onset diseases, including diabetes and breast cancer, when used in an embryo.

Ethical questions that should have been addressed regarding using whole-genome sequencing first in adults and then babies, now raise themselves for embryos.

This applies to privacy rights belonging to the embryo once it is born. Even assuming predictions can be accurately made, fore-knowledge of diseases that may surface in adulthood, like atrial fibrillation, cancer, or dementia, is not something an individual might want their parents, employers, or colleagues to know. And once the knowledge-genie is out of the bottle, its impossible to stuff it back in.

So, we keep trucking along with the technology before fully considering the ethical implications that would be unleashed. And initial thoughts may well change. [3]

Present Risk Ignored: And Virtues of the Old-Fashioned Way

The excitement of the new always seems to eclipse the banalities of the old. Certainly, infertile parents may require IVF, but as the hype around PGT-P increases, fertile would-be parents might be tempted to avail themselves of IVF to enable themselves of the service. That would be unwise.

IVF is associated with

IVF, then, should not be the first choice for conception.

Instead of searching for more knowledge, perhaps we should concentrate on safely using the knowledge we have.

[1] Genesis chapter 2

[2] at least four companies are advertising the service.

[3 Even bioethicist Julian Savelescu, who, as recently as June 2021, advocated a parental obligation of procreative beneficence, requiring selecting the child with the chance of the best life using PRS, changed his tune by October.

Visit link:
The Curse of Knowledge and Whole Genome Sequencing - American Council on Science and Health

Youth leaders encouraged to be ‘aware’ of issues – Fiji Times

Youth leaders in Lautoka have been encouraged to be aware of issues affecting their members.

Pacific Centre for Peacebuilding chairwoman Florence Swamy said a week-long youth empowerment training for the leaders would enable them to help their members deal with these societal issues.

During the course of this week, what we will do is deliver an intense training that will empower young people focusing on the needs that you yourselves have identified in the spaces that you live in, she said.

We will deliver this training using our restorative justice platform to equip you with tools that will help you to analyse your situation, to communicate your needs, hopes and fears and to dialogue and negotiate the differences that you have.

While opening the event, Minister for Youth and Sports Parveen Kumar said the training was for the benefit of youths that made up 40 per cent of Fijis population.

It is my sincere hope that the youth participants will develop their own minds in regards to their families and their future, he said.

This program is an opportunity for participants to gather and explore the topics of human rights and gender reproduction, healthy relationships and mental health care so that you may carry these lessons throughout your lives.

According to the Mr Kumar, there are more than 800 youth clubs registered under the ministry with more than 15,000 active members.

Go here to see the original:
Youth leaders encouraged to be 'aware' of issues - Fiji Times

Things In WALL-E That You Only Notice As An Adult – Looper

Not only does "WALL-E" have a premise that's both horrifically sad and unnervingly environmentally relevant, it's also largely about two robots that only say a half-dozen words or so between them. It's amazing, when you think about it, that audiences were able to connect with the story emotionally, and it's actually thanks in large part to songs from the 1969 movie musical "Hello, Dolly!" WALL-E has managed to find a VHS copy of the film that improbably still works, and repeated clips of just two songs serve as emotion shorthand at several different points of the story.

The jaunty, peppy "Put On Your Sunday Clothes" serves as the enervating, ironic choice to open the movie as we zoom in on the polluted, empty Earth, and then goes on to be a theme song for both WALL-E's curiosity and optimism, as well as a rallying cry for his robot brethren aboard the Axiom. Meanwhile, "It Only Takes A Moment" is the theme song for WALL-E and EVE's romantic connection. There's also a scene set to "La Vie En Rose" by Louis Armstrong, who was also part of "Hello, Dolly!" Between lifting the moods of an old musical and Thomas Newman's subtle, wonderful score, revisiting "WALL-E" as an adult really makes you consider how much music can accomplish in a nearly wordless film.

The rest is here:
Things In WALL-E That You Only Notice As An Adult - Looper

Bears in downtown Asheville aren’t going anywhere; here’s what to do if you see one – Citizen Times

Asheville residents spot a black bear downtown

Asheville resident Cari Barcas recorded a police officer escorting a black bear downtown on the afternoon of April 21, 2022.

Asheville Citizen Times

ASHEVILLE -It mayseem odd to see a black bear inthecity, but in Asheville, its not as rare as one might think.

On April 21, there was yet another sighting of a black bear taking a stroll downtown. Erin Kellem, manager at Woolworth Walk, managed to take a video of the bear as it wandered around the intersection of Haywood Street and Battery Park Avenue, around 3:30 p.m.

My co-worker caught sight of the bear and said, A bear!" Kellem said. "Customers kind of rushed outside and I rushed outside and had my camera and there were a whole lot of people who had crowded around and were taking pictures and watching."

NC Wildlife: Mama bear freed from plastic lid around neck in East Asheville

It is a high-traffic pedestrian and vehicle intersection and there were many others clustered on the sidewalks and driving by who witnessed the scene, she said.

Black bears are known to reside in and around the city, and sometimes they stumble into the heavily human-populated areas of downtown.

Its not uncommon to see a bear in downtown Asheville, said Ashley Hobbs, assistant black bear and furbearers biologist for the North Carolina Wildlife Resources Commission.

They go about their whole life cycles within Asheville city limits. We have bears that live in those little neighborhoods that surround the core area of downtown Asheville so its not uncommon for a bear to wander into the populated areas. In fact, we have bears that den for the winter right along I-240 within 5-feet of I-240.

Related: Bear takes a stroll through Rabbit Rabbit in downtown Asheville

Kellem had not personally seen a bear downtown before the encounter, though she knows others who have on occasion. A 20-year resident, Kellem is used to seeing them in her neighborhood in East Asheville.

I see them almost daily at home but not downtown, Kellem said.

Cari Barcas, associate director of Green Built Alliance, was leavingher downtown office building when she noticed acrowd.

I saw that there was a police vehicle and a bunch of people gawking. … As I approached the intersection, I saw a bear just standing there, actually trying to climb a tree, Barcas said.It was obviously a little claustrophobic and scared but was very peaceful and passive.

Police arrived and created a corridor around the bear to ensure it had space and a path to leave the area, Kellem said.

What I heard was that she picked a tree somewhere a block or two away and went up the tree, she said. I know in past times they will just leave a police officer in the area wherever the bear has gone up into the tree and once its dark and no one is around and there isnt a big fanfare, the bear will come down and make its way back to where it wants to be. The bear does not want that much attention.

Barcas took a video of the scene, which shows a police officer seemingly escorting the bear down the street.

The police officer was having to remind (people) to give a healthy boundary and give the bear some space so everyone could stay safe, Barcas said.

For eight years, Barcas has lived in Asheville. It wasnt her first bear sighting, but it was the first time shes seen one walking through the central business district downtown, she said.

Bear family plays at Isaac Dickson

Bear family plays at Isaac Dickson

Asheville Citizen Times

The number of bear sightings so far this spring and the number of many bears living in the city and regionis difficult to confirm, Hobbssaid. It is uncommon to see a bear in the more high-density pedestrian areas of the city.

Those sightings are less common because there are so many people around, especially in the middle of the day, but they do happen because the bears live and breathe right there in the middle of Asheville, Hobbs said.

Its really due to an expanding human population on top of an expanding bear population. So its kind of a no-brainer that we have more interactions as the years go on.

Bear sanctuaries no more: NC Wildlife OKs hunting, critics plan to appeal decision

Bear education and safety protocols are crucial for the community to learn and practice, especially as the city and surrounding areas grow, Barcas said.

As our community is developing and growing, I think its our responsibility as residents and as stewards of the land and this natural area to be responsible about how we interact with bears, she said.

In the videos, the bear can be seen wearing a tracking collar, which indicates that the bear is a female and part of the urban/suburban black bear study, Hobbs said.

Its looking at reproduction, what bears are eating around town, where theyre denning … within Asheville city limits, Hobbs said.

The bears dens are not relocated outside ofthe city because it would be ineffective, she said. Also, there is no place in the state to take bears where they wouldnt encounter people again.

Study: Bears in Asheville twice as big, reproduce in half the time of rural counterparts

These bears kind of have an internal GPS, if you will, where they know where they live and they want to stay in their home," Hobbs said. "Theres a lot of research that shows you can take a bear even a few states away and theyll make a beeline back to that spot where you picked it up. Its just not effective.

In other words, the bears are here to stay.

A bear sighting may be an exciting event, especially if a person hasnt seen one up close before. However, there are things a person should and shouldnt do to keep all humans and animals in the area safe. That may be sacrificing capturing a viral video and putting away the phone.

I make sure to keep a safe distance, Kellem said. I realized that a crowd was gathering and this bear had no way to escape and she was very stressed out. I actually stopped recording and came back inside when I realized I was kind of part of the problem. She did not want to be downtown anymore, and she did not have a way a direction that looked safe to head.

More: More bear-resistant trash cans on-the-way; 112 carts to shorten waiting list

Residents and visitors to the area should know what to do if they see a bear in the city or in the woods. The first thing is to make sure the bear has an escape route, Hobbs said.

You can do that by giving the bear a lot of space so that when they want to get away from you which they do when it comes to that fight or flight end of the spectrum they just want to get away from us, Hobbs said. Usually, when a bear sees you theyre going to turn tail and run.

In a case of a bear continuing to approach and theres no way to get away, the person should take a stance to attempt to scare it away.

Then youll want to put your arms over your head, get big and scary and kind of show that bear you mean business, Hobbs said.

In the exceedingly rare scenario of a bear continuing to pursue even after this, Dobbs said to find rocks or sticks or something else to throw at the bear to deter it.

Bear news: Black bear invites himself to techno dance party at home of East Asheville DJ

Dogs should be kept on a leash at all times to keep control at all times, she said.

Bears and dogs do not mix, Dobbs said. Never have your dog off-leash. And get you and your dog out of the area. Back away slowly in the opposite direction and again, make sure they always have an escape route.

NC Wildlife biologists: Bear that attacked couple on Blue Ridge Parkway climbed onto car

A human may have a fight or flight response, but its not a good idea to run, she said.

You should never run from a bear. That could trigger a predatory response or a chase response in them, Hobbs said. Thats their instinct of response when they see something running. So just keep your eye on the bear, watch what its doing and back away slowly out of the area.

The same rules apply in the woods, as well, she said.

If needed, call the NC Wildlife Commission helpline (866-318-2401) or local authorities for assistance.

It can be helpful for us to escort the bear to a safer spot, Hobbs said. If youre in a neighborhood area, it may not be uncommon to see them in the area so that may not warrant a call if you see a bear. But if you see a bear and it was getting into your trash or trying to get onto your porch or into your home, that would warrant a call, as well.

Bears are most active during dusk and dawn hours, she said, though bears in Asheville can be seen any time of the day. So, its recommended to always be always aware of ones surroundings.

Make sure that you can hear whats around you, Hobbs said. Make sure you dont have headphones in, and things like that, because these bears will give you a warning sign if you get too close. Theyll huff at you, theyll make popping noises with their jaw, and theyll let you know that youre too close.

If walking, bear spray or a bell or signal horn are effective but whistling, calling out Hey, bear!or making other noises can work to let the bear know of ones presence, too, she said.

Bears have an incredible sense of hearing so ninetimes out of 10 theyll get out of your way if you let them know youre in the area, Hobbs said.

BearWise is a national educational program developed by bear biologists and employed by the Wildlife Commission. The group offers some BearWise Basics for co-existing with bears:

For instructions on how to use bear spray and more guidelines on how to handle black bear encounters, visit bearwise.org.

Tiana Kennell is the food and dining reporter for the Asheville Citizen Times, part of the USA Today Network. Email her at tkennell@citizentimes.com or follow her on Twitter/Instagram @PrincessOfPage. Please help support this type of journalism with a subscription to the Citizen Times.

Excerpt from:
Bears in downtown Asheville aren't going anywhere; here's what to do if you see one - Citizen Times

American Academy of Neurology (AAN 2022) Braintale Showcases Together with Minoryx Data From Its Biomarker Platform for Disease and Treatment…

STRASBOURG, France--(BUSINESS WIRE)--Braintale, a medtech that is deciphering white matter, spin off from the Assistance Publique-Hpitaux de Paris, showcases, with Minoryx, a biotechnology company developing a treatment for X-linked Adrenoleukodystrophy (X-ALD), the results of the multicentric ADVANCE sub study with Braintale biomarker platform on the occasion of the American Academy of Neurology (AAN). The data were presented digitally on April 24th, 2022. This has also been the occasion to deepen the collaboration between the two companies.

Long underestimated in neurosciences, white matter, which represents 80% of the human brain, plays a key role in its proper functioning, development, and aging, whether normal or pathological. Accordingly, Braintale has been developing, since its inception in 2018, non-invasive, accessible, effective and clinically validated measurement and prediction tools for physicians treating patients suffering from brain diseases.

The Braintale platform includes AI-processed CE-marked digital solutions, deployed across three modules. Brainquant enables white matter quantification, brainScore powers clinical prediction and MyelinDex, monitors myelin integrity. Beyond demyelinating conditions, the platform has also been successfully implemented to monitor patients with amyotrophic lateral sclerosis (ALS) and predict recovery for comatose patients after cardiac arrest or trauma brain injury.

X-ALD is an inherited orphan neurodegenerative disease. The most common form is adrenomyeloneuropathy (AMN), which is a highly debilitating chronic disease affecting male and female X-ALD patients reaching adulthood. There is currently no approved treatment for AMN patients. X-ALD male patients can also develop the acute cerebral form, cALD, in both pediatric age and adulthood. cALD results in aggressive brain inflammation leading to permanent disability and death within 2-4 years.

Leriglitazone, a novel brain penetrant PPAR gamma agonist, recently showed significant clinical benefit in Minoryxs ADVANCE Phase II/III clinical trial in adult male patients with AMN. A separate phase II/III study in male pediatric patients with early stage cALD is ongoing (NEXUS).

On the occasion of the American Academy of Neurology, Braintale and Minoryx jointly presented additional results of a multicenter sub-study from the ADVANCE trial. The abstract is available online: https://index.mirasmart.com/aan2022/PDFfiles/AAN2022-002872.html

Beyond the characterization of MyelinDex as a relevant biomarker for monitoring disease progression and therapeutic efficacy, these data further support the efficacy of leriglitazone and its potential to improve myelin integrity in the brain of patients affected by AMN. These results pave the way to use of MyelinDex for disease and treatment monitoring in clinical trials as well as patient management in a hospital setting.

The collaboration between the two companies has expanded in order, notably, to implement the use of MyelinDex in additional clinical trials to further characterize beneficial impact of leriglitazone on myelin content, while contributing to a better understanding of X-ALD.

We are very excited to see the potential of Braintales technology to deliver precise and longitudinal analysis of white matter said Marc Martinell, CEO of Minoryx Therapeutics. These results are aligned with preclinical data showing the impact of leriglitazone on myelination.

Pleased with the success of our collaboration to date, Minoryx and Braintale teams have decided to extend their partnership exploring the use of biomarkers developed with the Braintale platforms. Now, together, we are contributing to better understand and improve follow-up, treatment, and stratification of patients with this devastating orphan disease, explains Julie Rachline, co-founder and CEO of Braintale through LallianSe.

About Braintale

Braintale is an innovative medtech company deciphering white matter to enable better care in neurology and intensive care with clinically validated prognostic solutions. With noninvasive, sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarkers platform to support clinical decision-making. Braintale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases, amyotrophic lateral sclerosis and neurodegenerative diseases. Based on more than 15 years of research and development, Braintale's products are developed to meet the medical needs and expectations of healthcare professionals for the benefit of patients.

Since its inception in 2018, the company has implemented a comprehensive quality management system and is now ISO 13485:2016 certified, with a suite of products available on the European market under the European Medical Device Regulation (MDR).

For more information, please visit http://www.braintale.eu

Continued here:
American Academy of Neurology (AAN 2022) Braintale Showcases Together with Minoryx Data From Its Biomarker Platform for Disease and Treatment...

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years – PR Newswire

STOCKHOLM, April 27, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational anti-amyloid-beta (A) protofibril antibody lecanemab (BAN2401) in people living with early Alzheimer's disease (AD), using disease modeling, was published in the peer-reviewed journal Neurology and Therapy. In this simulation, lecanemab treatment is estimated to slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of the disease.

The article focuses on the long-term clinical outcomes for people living with early AD (mild cognitive impairment (MCI) and mild AD) who have amyloid pathology, comparing lecanemab together with standard of care (SoC) versus SoC alone (acetylcholinesterase inhibitor or memantine). The simulation is based on patients being treated until they reach the moderate AD stage. The disease simulation model (AD ACE model1) is based on the results of the Phase 2b clinical trial evaluating the efficacy and safety of lecanemab, and from ADNI (Alzheimer's Disease Neuroimaging Initiative) study results.

Lecanemab treatment was estimated to slow the rate of disease progression, resulting in an extended duration of MCI due to AD and mild AD dementia and shortened the duration in moderate and severe AD dementia. In the model the mean time advancing to mild, moderate, and severe AD dementia was longer for patients in the lecanemab-treated group than for patients in the SoC group by 2.51 years, 3.13 and 2.34, respectively. The model also predicted a lower life-time probability of admission to institutional care with lecanemab treatment.

"The results from the simulation done by Eisai demonstrate the potential clinical value of lecanemab for patients with early AD and how it could slow the rate of disease progression, delay progression to AD dementia with several years and reduce the need for institutionalized care. Analyses such as these are important to understand the potential long-term effects for patient, families and society offered by lecanemab treatment beyond what can be seen in clinical trials. The outcome of the Clarity AD Phase 3 study will be essential to further refining this model, and we are looking forward to the topline results later this year," said Gunilla Osswald, BioArctic's CEO.

Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the second quarter 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial is expected by end of September 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

For further information, please contact:Gunilla Osswald, CEO E-mail: [emailprotected] Phone: +46 8 695 69 30

Oskar Bosson, VP Communications and IRE-mail: [emailprotected]Phone: +46 70 410 71 80

The information was released for public disclosure, through the agency of the contact persons above, on April 27, 2022, at 08:00 a.m. CET.

About lecanemab (BAN2401)Lecanemab is an investigational humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab selectively binds to, neutralize and eliminate soluble toxic A aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture, and market lecanemab for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Currently, lecanemab is being studied in a pivotal Phase 3 clinical study in symptomatic early AD (Clarity AD), following the outcome of the Phase 2b clinical study (Study 201). In addition, the Phase 3 clinical study, AHEAD 3-45, for individuals with preclinical (asymptomatic) AD, meaning they are clinically normal and have intermediate or elevated levels of brain amyloid, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium, funded by the National Institute on Aging, part of the National Institutes of Health, and Eisai. In 2021, DIAN-TU selected lecanemab for a clinical trial for dominantly inherited Alzheimer's disease as a background anti-amyloid treatment when exploring combination therapies with anti tau treatments in dominantly inherited Alzheimer's disease subjects. In June 2021, FDA granted lecanemab Breakthrough Therapy designation and in September 2021, Eisai initiated a rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer's disease under the accelerated approval pathway. In December 2021, FDA granted lecanemab Fast track designation and the second part of the rolling application was submitted. Eisai expects the rolling submission to be completed during the second quarter 2022.

About the collaboration between BioArctic and EisaiSince 2005, BioArctic has long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed in December 2007, and the Development and Commercialization agreement for the antibody BAN2401 back-up for Alzheimer's disease, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory filings, approvals, and sales milestones as well as royalties on global sales.

About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit http://www.bioarctic.com.

1Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer's disease Archimedes condition-event simulator: Development and validation. Alzheimers Dement (NY). 2018;4:76-88. Published 2018 Feb 16. doi:10.1016/j.trci.2018.01.001Tafazzoli and Kansal. Disease simulation in drug development, External validation confirms benefit in decision making. The Evidence Forum. 2018.https://www.evidera.com/wp-content/uploads/2018/10/07-Disease-Simulation-in-Drug-Development_Fall2018.pdf

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/modeling-published-in-neurology-and-therapy-suggests-that-lecanemab-could-delay-progression-to-alzhe,c3554093

The following files are available for download:

SOURCE BioArctic

Read the rest here:
Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years - PR Newswire

LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE PUBLISHED IN A PEER-REVIEWED…

TOKYO, April 26, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (A) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using simulation modeling was published in a peer-reviewed journal Neurology and Therapy. In this simulation, lecanemab treatment is estimated to potentially slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of mild cognitive impairment (MCI) due to AD and mild AD (collectively, early AD).

Eisai logo. (PRNewsFoto/Eisai Inc.)

The article describes the comparison of the long-term clinical outcomes for the people living with early AD who have amyloid pathology with standard of care (SoC) alone (including stable use of acetylcholinesterase inhibitor or memantine), and with lecanemab with SoC (lecanemab+SoC), using the disease simulation model (AD ACE model1,2) based on the results of a Phase IIb clinical trial (Study 201) evaluating the efficacy and safety of lecanemab. SoC data were estimated from ADNI (Alzheimer's Disease Neuroimaging Initiative) study results. It was shown that the estimated lifetime risk of disease progression to mild, moderate, and severe AD dementia from baseline could potentially be reduced by 7%, 13% and 10% in lecanemab+SoC, respectively, compared to SoC. In the model the mean time advancing to mild, moderate, and severe AD dementia was longer for patients in the lecanemab-treated group than for patients in the SoC group by 2.51 years (SoC vs. lecanemab+Soc: 3.10 vs.5.61 years), 3.13 (6.14 vs. 9.27 years) and 2.34 (9.07 vs.11.41 years) respectively. Subgroup analysis by age and disease severity at baseline also revealed a potentially greater impact on disease progression with earlier initiation of treatment with lecanemab. The incremental mean times for transition to mild and moderate AD dementia were 2.53 and 3.34 years, respectively, when treating MCI due to AD in a subgroup analysis compared to SoC.

Story continues

"With an increasing and aging global population, the number of people diagnosed with Alzheimer's disease will only continue to increase, making it an even more important and urgent public health priority. Alzheimer's disease is growing issue in regard to medical and nursing care costs, but also costs of informal care by family, leading to increased anxiety. The findings from the simulation model suggest early treatment with lecanemab may delay progression to the more severe stages of AD, potentially giving people living with early AD and their loved ones more time together and possibly reducing healthcare costs," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "These predicted and simulated long-term health outcomes provide insights for healthcare decision-makers regarding the potential clinical and socioeconomic value of lecanemab. Ongoing Phase 3 studies will soon be able to inform the model inputs and refine the findings. As part of Eisai's commitment to our human healthcare mission and transparency, we will continue to publish data and information about lecanemab."

Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the first quarter of Eisai's fiscal year 2022, which began April 1, 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval.

1 Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer's disease Archimedes condition-event simulator: Development and validation. Alzheimers Dement (NY). 2018;4:76-88. Published 2018 Feb 16. doi:10.1016/j.trci.2018.01.0012 Tafazzoli and Kansal. Disease simulation in drug development, External validation confirms benefit in decision making. The Evidence Forum. 2018.https://www.evidera.com/wp-content/uploads/2018/10/07-Disease-Simulation-in-Drug-Development_Fall2018.pdf

Media Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120

[Notes to editors]

1. About Lecanemab (BAN2401)Lecanemab is an investigational humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (A) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Currently, lecanemab is being developed as the only anti- A antibody that can be used for the treatment of early AD without the need for titration. With regard to the results from pre-specified analysis at 18 months of treatment, Study 201 demonstrated reduction of brain A accumulation (P<0.0001) and slowing of disease progression measured by ADCOMS* (P<0.05) in early AD patients. The study did not achieve super superiority its primary outcome measure** at 12 months of treatment. The Study 201 open-label extension was initiated after completion of the Core period and a Gap period off treatment of 9-59 months (average of 24 months, n=180 from core study enrolled) to evaluate safety and efficacy, and is underway.

Currently, lecanemab is being studied in a confirmatory Phase 3 clinical study in symptomatic early AD (Clarity-AD), following the outcome of the Phase 2 clinical study (Study 201). Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing. Furthermore, Eisai has initiated a lecanemab subcutaneous dosing Phase 1 study. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007.

* ADCOMS (AD Composite Score), developed by Eisai, combines items from the ADAS-Cog (AD Assessment Scale-cognitive subscale), Clinical Dementia Rating (CDR) and the MMSE (Mini-Mental State Examination) scales to enable a sensitive detection of changes in clinical functions of early AD symptoms and changes in memory. The ADCOMS scale ranges from a score of 0.00 to 1.97, with higher score indicating greater impairment.** An 80% or higher estimated probability of demonstrating 25% or greater slowing super superiority in clinical decline at 12 months treatment measured by ADCOMS from baseline compared to placebo.

2. About the Collaboration between Eisai and Biogen for Alzheimer's DiseaseEisai and Biogen are collaborating on the joint development and commercialization of AD treatments. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product.

3. About the Collaboration between Eisai and BioArctic for Alzheimer's DiseaseSince 2005, BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD. The commercialization agreement on the lecanemab antibody was signed in December 2007, and the development and commercialization agreement on the antibody lecanemab back-up for AD, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for AD. BioArctic has no development costs for lecanemab in AD.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/long-term-health-outcomes-using-simulation-model-of-investigational-lecanemab-in-patients-with-early-alzheimers-disease-published-in-a-peer-reviewed-journal-neurology-and-therapy-301533623.html

SOURCE Eisai Inc.

Go here to see the original:
LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE PUBLISHED IN A PEER-REVIEWED...

Three out of ten consultations in primary care and neurology are referred for headaches – Euro Weekly News

Quirnsalud has a headache programme in all its centers in the province of Alicante in which this condition is addressed comprehensively.

Three out of ten consultations in primary care and neurology are prompted by headaches and migraines, according to the Spanish Society of Neurology. The high incidence, says Dr. Erika Torres, neurologist and specialist in headaches at Quirnsalud Torrevieja and Alicante, delays access to a specialized consultation and increases the risk of chronic pain and disability by not obtaining a diagnosis, treatment and adequate follow-up of the patient.

Poorly controlled headaches can become a major cause of functional limitation and disability, causing repercussions that reduce the quality of life in all areas of life for the patient: work, family, leisure, etc. For this reason, indicates the neurologist from Quirnsalud Torrevieja and Alicante, it is essential to carry out an adequate and early diagnosis of the type of headache suffered in order to carry out the correct treatment, personalizing it, taking into account the specific characteristics of each patient.

Differences between migraines and headaches

Headaches are divided into two groups: a first group that includes primary headaches, including sporadic or chronic migraines and tension headaches in which the pain is not related to any disease, and a second group that includes secondary headaches in which there is an underlying cause for the headache and is a symptom of another disease such as eye disorders or fever. Tension-type headache would be the most prevalent type of primary headache, affecting 66% of the population.

Migraines are expressed with different symptoms than tension headache. As Dr. Torres explains, While migraine presents as a pain on one side of the head with pulsating characteristics or very intense pressure that can be accompanied by nausea, vomiting and discomfort from sounds, light or smells, tension-type headache is located in the whole head, with less intense pain than migraine, but uncomfortable because it is more constant and is usually associated with a feeling of dizziness and dullness.

To avoid chronic headaches, Dr. Torres recommends healthy lifestyle habits, not abusing painkillers and going to a specialist to receive adequate treatment.

Quirnsalud Alicante and Torrevieja, benchmarks in the treatment of headaches

Quirnsalud has a headache programme in all centeres in the province of Alicante in which headaches are addressed comprehensively. Patients have quick access to a consultant who, from the beginning, guides the patient about their type of headache, carrying out the necessary studies in each case. The program also includes the neurological nursing consultation service in which the patient is educated on pathology, their life habits are analyzed in detail and recommendations are made on what hygienic-dietary measures can help improve their quality of life.

This program also provides the patient with the most advanced treatments such as the administration of Botox for migraine and chronic tension-type headache, the new monoclonals with subcutaneous application for sporadic migraine and the rest of the therapeutic arsenal for less frequent headaches but just as important to alleviate suffering of the patient caused by conditions such as trigeminal neuralgia, occipital neuralgia, cluster headache, etc.

The patient has close contact with the professionals throughout and the health professionals will resolve all doubts quickly and continuously, both in person, by telephone and via email.

More information about headaches can be found in the video

Read more:
Three out of ten consultations in primary care and neurology are referred for headaches - Euro Weekly News

Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting -…

DUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022. FT218 is the Companys lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. The presentation highlights results from a questionnaire assessing patient preference for the once-nightly versus twice-nightly dosing regimen and another questionnaire assessing experiences with the second nightly dose in patients who switched from twice-nightly oxybates to FT218.

Twice-nightly oxybates for narcolepsy require a challenging dosing regimen that disrupts nighttime sleep. The results from the nocturnal adverse event questionnaire illustrate the burden that the second dose places on some patients, who already struggle with getting a full night of refreshing sleep, said Asim Roy, M.D., presenting author and Medical Director of the Ohio Sleep Medicine Institute. In my experience with patients in my practice, a once-at-bedtime option like FT218 would ease this burden and has the potential to be a major advance for the entire narcolepsy community.

At an interim data cutoff date of September 7, 2021, 35 participants who switched from twice-nightly oxybates to once-at-bedtime FT218 completed patient preference questionnaires three months after switching, with responses indicating that 94.3% (33/35 participants) preferred the once-nightly versus twice-nightly dosing regimen. As of the data cutoff, 60 participants who switched from twice-nightly oxybates to FT218 also completed a nocturnal adverse event questionnaire prior to switching to assess their experiences with the second nightly sodium oxybate dose. Results from the questionnaire follow:

These interim results from the ongoing RESTORE study highlight the preference for the once-at-bedtime versus twice-nightly dosing regimen among people who have switched from the twice-nightly formulation, said Douglas Williamson, M.D., Chief Medical Officer of Avadel. Further, they provide an insight into the challenges that patients face with a second, middle-of-the-night dose; challenges which may have been underappreciated due to the lack of other oxybate options. By eliminating the need for a second dose, FT218 has the potential to ease the burden facing sodium oxybate-eligible narcolepsy patients, if approved.

The abstract is available on the AAN website, and the virtual poster hall will be available to registrants until May 14, 2022.

About NarcolepsyNarcolepsy is a chronic neurological condition that impairs the brain's ability to regulate the sleep-wake cycle. The condition affects approximately one in 2,000 people in the United States with the cardinal symptom of EDS. Additional symptoms can vary by person and may include DNS, a sudden loss of muscle tone usually triggered by strong emotion (cataplexy), sleep paralysis and hypnagogic and hypnopompic hallucinations.

About FT218FT218 is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS or cataplexy in adults with narcolepsy.

In March 2020, Avadel completed the REST-ON trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in adults with narcolepsy. Among the three co-primary endpoints, FT218 demonstrated statistically significant and clinically meaningful results in EDS, the clinicians overall assessment of the patients functioning, and reduction in cataplexy attacks for all three evaluated doses compared to placebo.

In January 2018, the FDA granted FT218 Orphan Drug Designation for the treatment of narcolepsy based on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for those with narcolepsy due to the consequences of middle-of-the-night dosing of the approved product. A marketing application for FT218 is currently under review by the FDA.

Avadel is currently evaluating the long-term safety and tolerability of FT218 in the open-label RESTORE clinical study. For more information, visit: http://www.restore-narcolepsy-study.com.

AboutAvadel Pharmaceuticals plcAvadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS and cataplexy in adults with narcolepsy. For more information, please visit http://www.avadel.com.

Cautionary Disclosure Regarding Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, our expectations of the therapeutic benefits and tolerability of FT218, if approved; and patient preference and market acceptance of FT218, if approved. In some cases, forward-looking statements can be identified by the use of words such as will, may, could, believe, expect, look forward, on track, guidance, anticipate, estimate, project, next steps and similar expressions, and the negatives thereof (if applicable).

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risks and uncertainties described in the Risk Factors section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, which we filed with the Securities and Exchange Commission on March 16, 2022, and subsequent SEC filings.

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Investor Contact:Courtney TurianoStern Investor Relations, Inc. Courtney.Turiano@sternir.com (212) 698-8687

Media Contact:Nicole Raisch GoelzReal Chemistryngoelz@realchemistry.com(408) 568-4292

See more here:
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting -...

Progress in MS Therapeutic Development and Shifts in the Landscape – Neurology Live

Robert K. Shin, MD: Actually, it's more than a quarter-century as I think about it, right? We're approaching 30 years3 decadesof having approved therapies for multiple sclerosis. And some of the medications that were approved in the early 1990s are still being used today, which is kind of amazing. However, I think that with some of the data that that's been presented now, we're doing more and more head-to-head studies with active comparators. I think we can say that certainly for patients with active MS, we can see that there's a difference. That some MS therapies are more effective than other therapies, I think we should just be honest about that. They're not all created equal. And it doesn't really matter whether we focus on relapse rate or MRI parameters, disability progression, or combining them together into a metric like No Evidence of Disease Activity, whether it's NEDA-3 or, if you incorporate other components, NEDA-4. For the first time, we can say, Oh, if I use drug X over drug Y, I'm going to have a greater chance of seeing no evidence of disease activity.

I think that MS might be not totally unique, but unlike in some other fields of medicine, we have not agreed upon a firstline therapy. We don't have a consensus that when somebody is diagnosed with MS, we should start with drug X, and then if that's not tolerated. That kind of thing, which is common in other disease spaces. We just haven't come to a consensus in this space. But I think that if we look at studies that we're seeing reported out today, and what I think you can really see is that we should be honest and say that there are therapies that are more effective than others, there are strategies that will be more likely to result in shutting down of the disease process than others. Again, in our field, we're still debating sort of the timing of that optimization of our strategy.

But I do think that maybe there's an increasing shift, a recognition, that with the advent of therapies with greater efficacy, at least that option exists. I think more and more people are looking at using them earlier in the disease course rather than waiting until disability is apparent. And so to me, this is a positive shift. One thing I think that's kind of changed even how we think about MS, in terms of its clinical course, is the different disease processes. Because I do think in the past, we really thought in a very binary way. We thought that people would present with a relapsing form of the disease, and you know, heaven forbid that you transition into phase 2, like a progressive form of the disease. As if there's sort of this wide gulf between the two. Hopefully, you would never cross over in that regard. As we've seen at AAN and other meetings, data using different biomarkers, whether it's optical coherence tomography, serum neurofilament light, other biological markers, volumetric MRI, other more investigational MRI markerswhat's the common theme? We're seeing that neurodegeneration occurs from the beginning of the disease process, if not probably before the patient's even aware or the providers are even aware of the diagnosis. I would say, rather than two different stages, we now see them almost as overlapping. We see that there is a progressive neurodegenerative component that is occurring, as best we can tell, probably from the beginning of the disease process that is punctuated by relapses.

My opinion of why we were, I guess, misled is because of the existence of reserve, right? The ability of a young healthy person to compensate for the early stage means that it created the illusion that everything was fine until reserve runs out, and then the progression is more obvious. So to me, this has been the biggest shift in our understanding of the disease process because what this means is that we are developing a heightened sensitivity to any signs of progression. In other words, rather than waiting until somebody suddenly needs to use a cane or walker, what's the focus? Everyone's interested in things like cognition and biomarkers and different things to recognize this component as early as possible, really setting the stage for theoretically, hopefully, another class of therapies that will be to be particularly helpful for that. So there's been this shift, I would say, in sort of our thinking about MS, which I find very exciting because I think this maybe bodes well for the future. But as we discussed earlier, there are still some important steps that are necessary before we'll know how to best address that.

Transcript edited for clarity.

Original post:
Progress in MS Therapeutic Development and Shifts in the Landscape - Neurology Live

Race of people given Alzheimer’s blood tests may affect interpretation of results – EurekAlert

Three experimental blood tests used to identify people in early stages of Alzheimers disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine in St. Louis.

The study showed that a fourth blood test the PrecivityAD test, which is commercially available in the U.S. and Europe through C2N Diagnostics was equally effective at detecting early Alzheimers disease regardless of the race of the person being tested. Since cutoffs between normal and abnormal test scores usually are set based on predominantly white volunteers, tests that perform differently in Black compared to white populations put Black patients at disproportionate risk of misdiagnosis and receiving inappropriate medical care.

The study is published April 21 in the journal Neurology.

Most people are diagnosed with Alzheimers only after they become forgetful and confused. Such cognitive symptoms arise relatively late in the course of the disease, a decade or more after the brain first begins to change. Scientists are working to identify people earlier using blood tests that detect Alzheimers-associated proteins in the blood, also known as biomarkers. But the field of Alzheimers biomarker research is based on data collected from groups of mostly white participants, raising concerns about whether tests based on such biomarkers are equally valid in diverse populations.

When you use a limited study population as, unfortunately, scientists have traditionally done in Alzheimers research and then try to apply the results to everyone, including people of diverse backgrounds, you could exacerbate health inequities, said lead authorSuzanne Schindler, MD, PhD, an associate professor of neurology. My hope is that this paper will help illustrate the need to increase the diversity of participants in Alzheimers studies. My colleagues and I are working to develop a much larger, multicenter study to better evaluate racial differences in Alzheimers-related blood biomarkers. This is a major priority for us.

The study was not designed to find the reason some Alzheimers biomarkers lead to different results in Black individuals compared to white individuals, but the presence of other health conditions could play a role. In this study, Black participants were more likely than white participants to have high blood pressure (67% versus 45%) and diabetes (28% versus 5%). Both conditions are linked to Alzheimers disease and may influence performance of biomarker tests, the researchers said.

The PrecivityAD test uses high-resolution mass spectrometry to measure the ratio of the Alzheimers proteins amyloid beta 42 and amyloid beta 40, as well as apolipoprotein E (APOE), a protein that affects risk for Alzheimers disease. The underlying technology behind the PrecivityAD test was developed at Washington University in the laboratory ofRandall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology and a co-author on this paper. C2N, the maker of the PrecivityAD test, is a Washington University startup and is based in St. Louis.

The researchers analyzed the accuracy of the PrecivityAD test and blood tests for two other proteins neurofilament light protein and two forms of the protein tau in 76 pairs of Black and non-Hispanic white participants. The pairs were created by pulling from a pool of volunteers who take part in research studies through Washington Universitys Charles F. and JoanneKnight Alzheimer Disease Research Center(Knight ADRC), and were matched on age, gender, cognitive status and presence of the high-risk genetic variant ofAPOE.More than 90% of individuals had no cognitive impairment.

The researchers determined whether each individual had the brain changes of Alzheimers disease using brain scans, analyzing the cerebrospinal fluid that surrounds the brain and spinal cord, or both. High levels of amyloid plaques found on brain scans or specific changes in the cerebrospinal fluid are both considered gold-standard evidence of Alzheimers.

Only the PrecivityAD test accurately classified people by Alzheimers status regardless of self-identified race. The other three blood tests were not as accurate at classifying people by Alzheimers status. Worse, they also performed differently in Black individuals compared to white individuals.

The fact these risk models have not been tested in a lot of populations makes me wary, because Alzheimers is a global disease, said co-author Thomas K. Karikari, PhD, an assistant professor in the Department of Psychiatry and Neurochemistry at the University of Gothenburg in Gothenburg, Sweden. Karikari is originally from Ghana. For example,APOEis a very good predictor of Alzheimers disease in people of European ancestry, but for people of non-European ancestry, it may not be a good predictor. We have to study these risk models in a wide variety of people to understand where does it work, where does it not work, and what are the factors that affect the performance of these models.

Race norming, or calibrating tests separately for each race, is not a satisfactory solution to the problem of differences in biomarkers across racial groups, Schindler and Karikari said. Such a practice can create or worsen racial disparities. For example, until 2021 the NFL routinely used race-normed cognitive tests to evaluate former players for cognitive impairments linked to injuries sustained on the field. Such tests consistently underestimated the degree of impairment suffered by Black players, making it difficult for them to obtain appropriate compensation. Washington University physicians do not use race-norming when assessing cognitive function, saidJohn C. Morris, MD, the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology. Morris is the director of the Knight ADRC and a co-author on the paper.

Rather than trying to adjust for race in some way, it would be better to use tests that perform equally well in all individuals, Schindler said. Alternatively, we can try to understand the underlying factors that create these apparent racial differences and adjust for those underlying factors rather than race. What we dont want to do is to use these tests without evaluating their performance in diverse groups, because then we would fail in our duty to provide the best possible care to all.

Experimental study

People

Effect of race on prediction of brain amyloidosis by plasma A42/A40, phosphorylated tau, and neurofilament light.

21-Apr-2022

S.E. Schindler has received data on behalf of Washington University from C2N Diagnostics at no cost; T.K. Karikari reports no disclosures relevant to the manuscript; N.J. Ashton reports no disclosures relevant to the manuscript; R.L. Henson reports no disclosures relevant to the manuscript; K.E. Yarasheski is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; T. West is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; M.R. Meyer is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; K.M. Kirmess is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; Y. Li reports no disclosures relevant to the manuscript; B. Saef reports no disclosures relevant to the manuscript; K.L. Moulder reports no disclosures relevant to the manuscript; D. Bradford reports no disclosures relevant to the manuscript; A.M. Fagan has received research funding from Biogen, Centene, Fujirebio and Roche Diagnostics. She is a member of the scientific advisory boards for Roche Diagnostics, Genentech and Diadem. She consults for DiamiR and Seimens Healthcare Diagnostics Inc.; B.A. Gordon reports no disclosures relevant to the manuscript; T.L.S. Benzinger has investigator-initiated research funding from the NIH, the Alzheimers Association, the Barnes-Jewish Hospital Foundation and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). She participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jaansen, and Roche. She serves as an unpaid consultant to Eisai and Siemens. She is on the Speakers Bureau for Biogen; J. Balls-Berry is a member of the patient advisory board and receives financial support for Dartmouth University project Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings (UPFRONT; NCT03985449); R.J. Bateman co-founded C2N Diagnostics. Washington University and Dr. Bateman have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. He receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with Dr. Bateman as coinventor, have submitted the US provisional patent application Plasma Based Methods for Detecting CNS Amyloid Deposition. He consults for Roche, Genentech, AbbVie, Pfizer, Boehringer-Ingelheim, and Merck; C. Xiong consults for Diadem; H. Zetterberg has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; K. Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; J.C. Morris, MD is the Chair of the Research Strategy Council of the Cure Alzheimers Fund.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
Race of people given Alzheimer's blood tests may affect interpretation of results - EurekAlert

Faster accumulation of cardiovascular risk factors linked to increased dementia risk – EurekAlert

EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, APRIL 20, 2022

MINNEAPOLIS Cardiovascular disease risk factors, like high blood pressure, diabetes, obesity and smoking, are believed to play key roles in the likelihood of developing cognitive decline, dementia, and Alzheimers disease. A new study suggests that people who accumulate these risk factors over time, at a faster pace, have an increased risk of developing Alzheimers disease dementia or vascular dementia, compared to people whose risk factors remain stable throughout life. The research is published in the April 20, 2022, online issue of Neurology, the medical journal of the American Academy of Neurology.

Our study suggests that having an accelerated risk of cardiovascular disease, quickly accumulating more risk factors like high blood pressure and obesity, is predictive of dementia risk and associated with the emergence of memory decline, said study author Bryn Farnsworth von Cederwald, PhD, of Ume University in Sweden. As a result, earlier interventions with people who have accelerated cardiovascular risks could be an effective way to help prevent further memory decline in the future.

The study looked at 1,244 people with an average age of 55 who were considered healthy in terms of cardiovascular health and memory skills at the start of the study. Participants were given memory tests, health examinations, and completed lifestyle questionnaires every five years for up to 25 years.

Of all participants, 78 people, or 6%, developed Alzheimers disease dementia during the study and 39 people, or 3%, developed dementia from vascular disease.

Cardiovascular disease risk was determined by using the Framingham Risk Score which predicts the 10-year risk of a cardiovascular event. It looks at factors including a persons age, sex, body mass index (BMI), blood pressure and whether they smoke or have diabetes. Participants started the study with an average 10-year risk between 17% and 23%.

Researchers determined who had an accelerated cardiovascular disease risk by comparing participants to the average progression of cardiovascular disease risk.

Researchers found that cardiovascular disease risk remained stable in 22% of participants, increased moderately over time in 60%, and rose at an accelerated pace in 18% of people.

People in the study with stable cardiovascular disease risk had an average 20% risk of a cardiovascular event over 10 years throughout the study, while those with a moderate increased risk went from 17% to 38% over the course of the study and those with an accelerated risk went from a 23% to 62% increased risk by the end of the study.

Researchers determined that when compared to people with a stable cardiovascular disease risk, people with an accelerated cardiovascular disease risk had a three to six times greater chance of developing Alzheimers disease dementia and a three to four times greater risk of developing vascular dementia. They also had up to a 1.4 times greater risk of memory decline in middle age.

Several risk factors were elevated in people with an accelerated risk, indicating that such acceleration may come from an accumulation of damage from a combination of risk factors over time, said Farnsworth von Cederwald. Therefore, it is important to determine and address all risk factors in each person, such as reducing high blood pressure, stopping smoking and lowering BMI, rather than just address individual risk factors in an effort to prevent or slow dementia.

A limitation of the study was the inability to determine whether the decline leading to dementia is initiated by an accelerated cardiovascular disease risk. Farnsworth von Cederwald said it cannot be ruled out that other factors may also contribute, so more research is needed.

The study was funded by the Swedish Brain Foundation, Knut and Alice Wallenberg Foundation, and Swedish Foundation for Humanities and Social Sciences.

Learn more about dementia at BrainandLife.org, home of the American Academy of Neurologys free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

When posting to social media channels about this research, we encourage you to use the hashtags #Neurology and #AANscience.

The American Academy of Neurology is the worlds largest association of neurologists and neuroscience professionals, with over 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, stroke, migraine, multiple sclerosis, concussion, Parkinsons disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the article here:
Faster accumulation of cardiovascular risk factors linked to increased dementia risk - EurekAlert

Nanotechnology has much to offer Nigeria but research needs support – The Conversation

Nanotechnology is one of the engines of the fourth industrial revolution. The global market of nanotechnology-enabled products stood at approximately US$1.6 trillion in 2014. In one estimate, the industry could generate 6 million jobs and account for 10% of global GDP by 2030.

Nanotechnology creates, uses and studies materials at nanoscale - one nanometre is a billionth of a metre. Some of these materials occur in nature. DNA, proteins and viruses are examples. Others can be created by slicing larger molecules into smaller ones or by building up atoms into nanoparticles.

Nanomaterials have special physical, optical, biological, chemical, electrical and mechanical attributes. For instance, graphene is a very light nanomaterial but is several hundred times stronger than steel.

The field of nanotechnology has blossomed to encompass physics, chemistry, engineering, materials and biological sciences. It has applications in agriculture, industry, medicine, the environment and consumer products.

The big players in nanotechnology investments are the US, Japan, the EU and South Korea. Along with China, they accounted for 72.12% of the nanotech patents in the US patent and trademark office in 2016. Brazil, Russia and India are also very active.

Egypt, South Africa, Tunisia, Nigeria and Algeria lead the field in Africa. Since 2006, South Africa has been developing scientists, providing infrastructure, establishing centres of excellence, developing national policy and setting regulatory standards for nanotechnology. Companies such as Mintek, Nano South Africa, SabiNano and Denel Dynamics are applying the science.

In contrast, Nigerias nanotechnology journey, which started with a national initiative in 2006, has been slow. It has been dogged by uncertainties, poor funding and lack of proper coordination. Still, scientists in Nigeria have continued to place the country on the map through publications.

In addition, research clusters at the University of Nigeria, Nsukka, Ladoke Akintola University of Technology and others have organised conferences. Our research group also founded an open access journal, Nano Plus: Science and Technology of Nanomaterials.

To get an idea of how well Nigeria was performing in nanotechnology research and development, we turned to SCOPUS, an academic database.

Our analysis shows that research in nanotechnology takes place in 71 Nigerian institutions in collaboration with 58 countries. South Africa, Malaysia, India, the US and China are the main collaborators. Nigeria ranked fourth in research articles published from 2010 to 2020 after Egypt, South Africa and Tunisia.

Five institutions contributed 43.88% of the nations articles in this period. They were the University of Nigeria, Nsukka; Covenant University, Ota; Ladoke Akintola University of Technology, Ogbomoso; University of Ilorin; and University of Lagos.

The number of articles published by Nigerian researchers in the same decade was 645. Annual output grew from five articles in 2010 to 137 in the first half of 2020. South Africa published 2,597 and Egypt 5,441 from 2010 to 2020. The global total was 414,526 articles.

The figures show steady growth in Nigerias publications. But the performance is low in view of the fact that the country has the most universities in Africa.

The research performance is also low in relation to population and economy size. Nigeria produced 1.58 articles per 2 million people and 1.09 articles per US$3 billion of GDP in 2019. South Africa recorded 14.58 articles per 2 million people and 3.65 per US$3 billion. Egypt published 18.51 per 2 million people and 9.20 per US$3 billion in the same period.

There is no nanotechnology patent of Nigerian origin in the US patents office. Standards dont exist for nano-based products. South Africa had 23 patents in five years, from 2016 to 2020.

Nigerian nanotechnology research is limited by a lack of sophisticated instruments for analysis. It is impossible to conduct meaningful research locally without foreign collaboration on instrumentation. The absence of national policy on nanotechnology and of dedicated funds also hinder research.

The size of Nigerias economy points to great potential for research and the development of patents and products.

Nanotechnology would benefit Nigeria in several ways. In agriculture, nanomaterials can be exploited as slow release fertilisers and eco-friendly agents against pests and diseases. There are applications in renewable and clean energy generation, through biofuels and solar panels.

Read more: How new energy technologies can help South Africa ease its energy crunch

In security, nanomaterials in gadgets and vehicles can enhance protection and capabilities of personnel. For example, there is potential for smart uniforms with ultraviolet protection, antimicrobial properties, camouflaging, and resistance to water and fire.

Nanomaterials can make drinking water safe through disinfection and removal of chemical pollutants. In healthcare, antimicrobial nanofabrics can help prevent hospital-acquired infections.

Read more: Nanomedicine could revolutionise the way we treat TB. Here's how

Through numerous applications, Nigeria can use nanotechnology to deliver on development goals. Ending poverty and promoting sustainable industrialisation are just two.

In February 2018, Nigerias science and technology minister unveiled a national steering committee on nanotechnology policy. But the policy is yet to be approved by the federal government. In September 2021, I presented a memorandum to the national council on science, technology and innovation to stimulate national discourse on nanotechnology.

Government should implement the outcomes of these efforts without delay. It can:

approve a national policy,

set up an agency to coordinate implementation,

make funds available for infrastructure, and

establish a centre of excellence.

The countrys trading and diplomatic partners may be of aid. The private sector also has a part to play. It can provide funds for research, offer scholarships and donate instruments. Adopting nanotechnology in commercial activities will also promote its development in Nigeria.

Link:
Nanotechnology has much to offer Nigeria but research needs support - The Conversation

ERDC researchers analyze resilience in nanotechnology supply chains – The Vicksburg Post – Vicksburg Post

Researchers at the U.S. Army Engineer Research and Development Center (ERDC) are analyzing the need for increased resilience in nanotechnology supply chains.

Manufacturing and distribution of products require a complex network of suppliers and distributors that constitute supply chains. In todays world, most people are aware of supply chains and have probably been affected by supply chain disruptions caused by the COVID-19 pandemic.

Supply chains are pivotal in the production of both military and civilian products and technologies, said Dr. Igor Linkov, senior scientific technical manager for ERDCs Environmental Laboratory (EL). Our team looked at two questions: a) how do you assess the impacts of supply chain disruptions on the manufacturing bottom line and product availability to consumers, and b) how do you mitigate supply chain disruption and increase their ability to recover, particularly when the various secondary or tertiary contributors to a supply chain are poorly characterized?

In the past, supply chains were optimized to be efficient and lean. Companies like suppliers with low labor costs and predictable and inexpensive material availabilities; suppliers having mature capabilities to ship basic or composite materials to manufacturing centers and consumers alike are also popular. However, when there is a crisis and supply chains are disrupted, efficiency may not equal the ability to recover from the disruption.

For example, it is efficient to have one supplier that covers all the material requirements for a given product, but it is not resilient because if that supplier is disrupted then the whole supply chain is impacted. On the other hand, having multiple suppliers for each component may not be efficient because of the extra costs required to maintain multiple suppliers with variable product lines, but if one supplier is disrupted, other suppliers are available, and the supply chain is less disrupted and far more capable of expeditious recovery.

The biggest thing is to understand how to balance efficiency and resilience in supply chains, Linkov said. Understanding this, organizations can work to create a more resilient supply chain for the products and services they provide.

In addition to analyzing supply chains in general, the ERDC research team also looked at supply chains as they relate to the nanotechnology industry and specifically to COVID vaccine production. Their results are published in recent paper in the journal Vaccine (https://www.sciencedirect.com/science/article/pii/S0264410X22001724?via%3Dihub), as well as in Current Opinion in Chemical Engineering (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549437/).

This research, as well as other ERDC work related to climate response and recovery, is led by Dr. Benjamin Trump, a research social scientist in ELs executive office.

Nanotechnology is an emerging technology that is the manipulation of matter on an almost atomic scale to produce new structures, materials and devices. Nanotechnology is helping to improve many technology and industry sectors, including medicine, transportation and environmental science.

One thing we looked at was the nanotechnology supply chain as it applied to vaccines, said Trump. Nano-enabled components are quickly becoming vital to vaccine production. COVID-19 vaccine candidates, for instance, used nano-enabled components to improve vaccine efficacy and delivery in vivo.

Nanotechnology allows properties of materials to be changed in a controlled way to address specific needs. In military applications, nanomaterials are used to make warfighters clothing waterproof and self-cleaning. Nanomaterials can also be used to heal wounds nanomaterials can make a shirt automatically act as an antiseptic if the warfighter is wounded.

We have tried to attract attention to the problem that in manufacturing nano-enabled products, supply chain operations are foundational logistical challenges that require careful governance, Trump said. We tried to look at how supply chain works for nano-enabled products and use this as a way to illustrate the importance of resilience and efficiency in supply chains.

Read this article:
ERDC researchers analyze resilience in nanotechnology supply chains - The Vicksburg Post - Vicksburg Post